

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/004548

International filing date: 11 February 2005 (11.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/544,534

Filing date: 13 February 2004 (13.02.2004)

Date of receipt at the International Bureau: 11 March 2005 (11.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1291380

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 02, 2005


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/544,534

FILING DATE: *February 13, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US05/04548

Certified by



Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

2026 US PTO
021304**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**
This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53(c).**Express Mail Label N . EV 195882685 US****Docket Number: 830002-2013****INVENTOR(S)**

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Gavril	Pasternak	Department of Neurology Memorial Sloan-Kettering Cancer Center 1275 York Avenue New York, NY 10021
Ying-Xian	Pan	Department of Neurology - Room 907K Memorial Sloan-Kettering Cancer Center 425 East 68 Street (bet. 1st /York Aves.) New York, NY 10021

 Additional inventors are being named on the _____ separately numbered sheets attached hereto**TITLE OF THE INVENTION (500 characters max.)****IDENTIFICATION AND CHARACTERIZATION OF MULTIPLE SPLICE VARIANTS OF THE MU OPIOID RECEPTOR GENE**

Direct all correspondence to:

CORRESPONDENCE ADDRESS Customer Number**20999** Firm or Individual NameWilliam F. Lawrence, Esq.
FROMMER LAWRENCE & HAUG LLP

Address

745 Fifth Avenue

City

New York

State

New York

Zip

10151

County

New York

Telephone

(212) 588-0800

Fax

(212) 588-0500

ENCLOSED APPLICATION PARTS (Check all that apply)

- Specification,
52 pages (47 Specification-pp. 1-47; numbered paragraphs 1-21 on pp. 48-50; 1 p. Abstract-p. 52).
 Drawings (26 pages, Figures 1A-6E)
 Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

- Applicant claims small entity status. See 37 CFR 1.27.
 A check or money order is enclosed to cover the filing fees
 The Commissioner is hereby authorized to charge filing
fees and credit Deposit Account Number: **50-0320**
 Payment by credit card. Form PTO-2038 is attached.

FILING FEE
AMOUNT (\$)
\$80.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

- No
 Yes, the name of the U.S. government agency and the Government contract number are:

National Institute on Drug Abuse (Grant Number DA02615 and DA07241); Senior Scientist Award to Gavril Pasternak (Grant Number DA00220); a research grant to Ying-Xian Pan (Grant Number DA13997); a grant from the National Genetics Foundation; and a core grant to Memorial Sloan-Kettering Cancer Center, NY, NY from the National Cancer Institute (Grant Number CA08748).

Respectfully submitted,

SIGNATURE

Deborah L. Lu

DATE

February 13, 2004

TYPED OR PRINTED NAME

William F. Lawrence, Esq.
Amy Leahy, Esq.
Deborah L. LuREGISTRATION NO.
(if appropriate)**28,029
47,739
50,940**

Docket Number:

830002-2013

TELEPHONE

(212) 588-0800

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

00175711

2251
60/544534
021304

"Express Mail" mailing label number

EV 195882268 US


Date of Deposit

February 13, 2004

I hereby certify that this paper or fee, and a Provisional patent application and accompanying papers, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Charles B. Jackson

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)

TITLE OF THE INVENTION

IDENTIFICATION AND CHARACTERIZATION OF MULTIPLE
SPLICE VARIANTS OF THE MU OPIOID RECEPTOR GENE

RELATED APPLICATIONS/PATENTS & INCORPORATION BY REFERENCE

5 Each of the applications and patents cited in this text, as well as each document or reference cited in each of the applications and patents (including during the prosecution of each issued patent; “application cited documents”), and each of the PCT and foreign applications or patents corresponding to and/or claiming priority from any of these applications and patents, and each of the documents cited or referenced in each of the application cited documents, are hereby
10 expressly incorporated herein by reference. More generally, documents or references are cited in this text, either in a Reference List before the claims, or in the text itself; and, each of these documents or references (“herein cited references”), as well as each document or reference cited in each of the herein-cited references (including any manufacturer’s specifications, instructions, etc.), is hereby expressly incorporated herein by reference.

15 STATEMENT OF RIGHTS TO INVENTION MADE UNDER
FEDERALLY SPONSORED RESEARCH

This work was supported by the government, in part, by grants from the National Institute on Drug Abuse (DA02615 and DA07241); a Senior Scientist Award (DA00220) to Gavril W. Pasternak; a research grant (DA13997) to Ying-Xian Pan; a grant from the National Genetics Foundation; and a core grant to Memorial Sloan-Kettering Cancer Center, New York, NY (CA08748) from the National Cancer Institute. The government may have certain rights to this invention.

TECHNICAL FIELD

The present invention relates to mu-opioid receptor-1 (MOR-1) splice variant polypeptides, to DNA sequences encoding the splice variants, to DNA sequences encompassing non-coding region splice variants, to methods of screening compositions for agonists and antagonists of the splice variant receptor activities and to methods of measuring splice variant binding activities.

BACKGROUND ART

Opiates are drugs derived from opium and include morphine, codeine and a wide variety of semisynthetic opioid congeners derived from them and from thebaine, another component of opium. Opioids include the opiates and all agonists and antagonists with morphine-like activity and naturally occurring endogenous and synthetic opioid peptides. Morphine and other morphine-like opioid agonists are commonly used pharmaceutically to produce analgesia.

There are now many compounds with pharmacological properties similar to those produced by morphine, but none has proven to be clinically superior in relieving pain.

References to morphine herein will be understood to include morphine-like agonists as well.

- 10 The effects of morphine on human beings are relatively diverse and include analgesia, drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous systems. Pasternak (1993) Clin. Neuropharmacol. 16:1. Doses of morphine need to be tailored based on individual sensitivity to the drug and the pain-sparing needs of the individual. For instance, the typical 15 initial dose of morphine (10mg/70kg) relieves post-operative pain satisfactorily in only two-thirds of patients. Likewise, responses of an individual patient may vary dramatically with different morphine-like drugs and patients may have side effects with one such drug and not another. For example, it is known that some patients who are unable to tolerate morphine may have no problems with an equianalgesic dose of methadone. The mechanisms underlying 20 variations in individual responses to morphine and morphine-like agonists have not been defined.

- The analgesic effects of morphine are transduced through opioid receptors in the central nervous system (CNS), located at both spinal and multiple supraspinal sites. Morphine and other agonists induce profound analgesia when administered intrathecally or instilled locally into the dorsal horn of the spinal cord. Several mechanisms of action are believed to mediate the 25 inhibition of nociceptive reflexes from reaching higher centers of the brain, including the inhibition of neurotransmitter release by opioid receptors on the termini of primary afferent nerves and post synaptic inhibitory actions on interneurons and on the out-put neurons of the spinothalamic tract.

- Profound analgesia can also be produced by the instillation of morphine into the third 30 ventricle or within various sites in the midbrain and medulla, most notably the periaqueductal gray matter, the nucleus raphe magnus, and the locus ceruleus. Although the neuronal circuitry

responsible has not been defined, these actions produce enhanced activity in the descending aminergic bulbospinal pathways that exert inhibitory effects on the processing of nociceptive information in the spinal cord. Simultaneous administration of morphine at both spinal and supraspinal sites results in a synergized analgesic response, with a ten-fold reduction in the total 5 dose of morphine necessary to produce equivalent analgesia at either site alone.

Morphine also exerts effects on the neuroendocrine system. Morphine acts in the hypothalamus to inhibit the release of gonadotropin releasing hormone (GnRH) and corticotropin-releasing factor (CRF), thus decreasing circulating concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH), and adrenocorticotropin (ACTH), and β -endorphin. As a result of the decreased concentrations of pituitary trophic hormones, the 10 concentrations of testosterone and cortisol in the plasma decline. The administration of opiates increases the concentration of prolactin (PRL) in plasma, most likely by reducing the dopaminergic inhibition of PRL secretion. With chronic administration, tolerance eventually develops to the effects of morphine on hypothalamic releasing factors.

Opiates can interfere with normal gastrointestinal functioning. Morphine decreases both 15 gastric motility and the secretion of hydrochloric acid in the stomach. Morphine may delay passage of gastric contents through the duodenum for as long as 12 hours. Morphine also decreases biliary, pancreatic and intestinal secretions and delays the digestion of food in the small intestine. Propulsive peristaltic waves in the colon are diminished or abolished after 20 administration of morphine and commonly, constipation occurs. For a detailed review of the physiological effects of morphine, see Reisine and Pasternak (1996) Goodman & Gilman's The pharmacological basis of therapeutics, Ninth Edition (Hardman et al. eds.) McGraw-Hill pp. 521-555.

Morphine also exerts effects on the immune system. The most firmly established effect 25 of morphine is its ability to inhibit the formation of rosettes by human lymphocytes. The administration of morphine to animals causes suppression of the cytotoxic activity of natural killer cells and enhances the growth of implanted tumors. These effects appear to be mediated by actions within the CNS. By contrast, β -endorphin enhances the cytotoxic activity of human monocytes in vitro and increases the recruitment of precursor cells into the killer cell population; 30 this peptide also can exert a potent chemotactic effect on these cells. A novel type of receptor (designated ϵ) may be involved. These effects, combined with the synthesis of

Proopiomelanocortin (POMC) and preproenkephalin by various cells of the immune system, have stimulated studies of the potential role of opioids in the regulation of immune function. Sibinga and Goldstein (1988) Annu. Rev. Immunol. 6:219.

Side effects resulting from the use of morphine range from mild to life threatening.

- 5 Morphine causes constriction of the pupil by an excitatory action on the parasympathetic nerve innervating the pupil. Morphine depresses the cough reflex through inhibitory effects on the cough centers in the medulla. Nausea and vomiting occur in some individuals through direct stimulation of the chemoreceptor trigger zone for emesis, in the postrema of the medulla. Therapeutic doses of morphine also result in peripheral vasodilatation, reduced peripheral
10 resistance and an inhibition of baroreceptor reflexes in the cardiovascular system. Additionally, morphine provokes the release of histamines, which can cause hypotension. Morphine depresses respiration, at least in part by direct effects on the brainstem regulatory systems. In humans, death from morphine poisoning is nearly always due to respiratory arrest. Opioid antagonists can produce a dramatic reversal of severe respiratory depression and naloxone is currently the
15 treatment of choice. High doses of morphine and related opioids can produce convulsions that are not always relieved by naloxone.

The development of tolerance and physical dependence with repeated use is a characteristic feature of all opiates. Dependence seems to be closely related to tolerance, since treatments that block tolerance to morphine also block dependence. In vivo studies in animal
20 models demonstrate the importance of neurotransmitters and their interactions with opioid pathways in the development of tolerance to morphine. Blockade of glutamate actions by noncompetitive and competitive NMDA (N-methyl-D-aspartate) antagonists blocks morphine tolerance. Trujillo and Akil (1991) Science 251:85; and Elliott et al. (1994) Pain 56:69. Blockade of the glycine regulatory site on NMDA receptors has similar effects to block
25 tolerance. Kolesnikov et al. (1994) Life Sci. 55:1393. Administering inhibitors of nitric oxide synthase in morphine-tolerant animals reverses tolerance, despite continued opioid administration. Kolesnikov et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:5162. These studies indicate several important aspects of tolerance and dependence. First, the selective actions of drugs on tolerance and dependence demonstrate that analgesia can be dissociated from these two
30 unwanted actions. Second, the reversal of preexisting tolerance by NMDA antagonists and nitric oxide synthase inhibitors indicates that tolerance is a balance between activation of processes

and reversal of those processes. These observations suggest that, by use of selective agonists and/or antagonists, tolerance and dependence in the clinical management of pain can be minimized or disassociated from the therapeutic effects.

In addition to morphine, there are a variety of opioids suitable for clinical use. These include, but are not limited to, Levorphanol, Meperidine, Fentanyl, Methadone, Codeine, Propoxyphene and various opioid peptides. Certain opioids are mixed agonists/antagonists and partial agonists. These include pentazocine, nalbuphine, butorphanol, and buprenorphine. The pharmacological effects of levorphanol closely parallel those of morphine although clinical reports suggest that levorphanol produces less nausea.

Meperidine exerts its chief pharmacological effects on the central nervous system and the neural elements in the bowel. Meperidine produces a pattern of effects similar but not identical to those described for morphine. In equianalgesic doses, meperidine produces as much sedation, respiratory depression, and euphoria as morphine. The pattern of unwanted side effects that follow the use of meperidine are similar to those observed after equianalgesic doses of morphine, except that constipation and urinary retention are less common.

Fentanyl is a synthetic opioid estimated to be 80 times as potent as morphine as an analgesic. High doses of fentanyl can result in severe toxicity and produce side effects including muscular rigidity and respiratory depression.

Methadone is an opioid with pharmacological properties similar to morphine. The properties of methadone include effective analgesic activity, efficacy by the oral route and persistent effects with repeated administration. Side effects include detection of miotic and respiratory-depressant effects for more than 24 hours after a single dose, and marked sedation is seen in some patients. Effects on cough, bowel motility, biliary tone and the secretion of pituitary hormones are qualitatively similar to those of morphine. In contrast to morphine, codeine is approximately 60% as effective orally as parenterally, both as an analgesic and as a respiratory depressant.

Codeine has an exceptionally low affinity for opioid receptors, and the analgesic effect of codeine is due to its conversion to morphine. However, codeine's antitussive actions probably involve distinct receptors that bind codeine specifically.

Propoxyphene produces analgesia and other CNS effects that are similar to those seen with morphine. It is likely that at equianalgesic doses the incidence of side effects such as

nausea, anorexia, constipation, abdominal pain, and drowsiness would be similar to those of codeine.

Opioid antagonists have therapeutic utility in the treatment of overdosage with opioids. As understanding of the role of endogenous opioid systems in pathophysiological states increases, additional therapeutic indications for these antagonists will emerge. If endogenous opioid systems have not been activated, the pharmacological actions of opioid antagonists depend on whether or not an opioid agonist has been administered previously, the pharmacological profile of that opioid and the degree to which physical dependence on an opioid has developed. The antagonist naloxone produces no discernible subjective effects aside from slight drowsiness. Naltrexone functions similarly, but with higher oral efficacy and a longer duration of action. Currently, naloxone and naltrexone are used clinically to treat opioid overdoses. Their potential utility in the treatment of shock, stroke, spinal cord and brain trauma, and other disorders that may involve mobilization of endogenous opioids remains to be established.

The complex interactions of morphine and drugs with mixed agonist/antagonist properties are mediated by multiple classes of opioid receptors. Opioid receptors comprise a family of cell surface proteins, which control a range of biological responses, including pain perception, modulation of affective behavior and motor control, autonomic nervous system regulation and neuroendocrinological function. There are three major classes of opioid receptors in the CNS, designated mu, kappa and delta, which differ in their affinity for various opioid ligands and in their cellular distribution. The different classes of opioid receptors are believed to serve different physiologic functions. Olson et al. (1989) Peptides 10:1253; Lutz and Pfister (1992) J. Receptor Res. 12:267; and Simon (1991) Medicinal Res. Rev. 11:357. Morphine produces analgesia primarily through the mu-opioid receptor. However, among the opioid receptors, there is substantial overlap of function as well as of cellular distribution.

The mu-opioid receptor mediates the actions of morphine and morphine-like opioids, including most clinical analgesics. In addition to morphine, several highly selective agonists have been developed for mu-opioid receptors, including [D-Ala²,MePhe⁴,Gly(ol)⁵]enkephalin (DAMGO), levorphanol and methadone. Differential sensitivity to antagonists, such as naloxonazine, indicates the pharmacological distinctions between the mu-opioid receptor

subtypes, mu₁ and mu₂. Several of the opioid peptides will also interact with mu-opioid receptors.

There are three distinct families of endogenous opioid peptides, the enkephalins, endorphins and dynorphins, where each peptide is derived from a distinct precursor polypeptide.

- 5 Mu-opioid receptors have a high affinity for the enkephalins as well as beta-endorphin and dynorphin A. For review, see Reisine and Pasternak (1996).

Members of each known class of opioid receptor have been cloned from human cDNA and their predicted amino acid sequences have been determined. Yasuda et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6736; and Chen et al. (1993) Mol. Pharmacol. 44:8. The opioid receptors 10 belong to a class of transmembrane spanning receptors known as G-protein coupled receptors. G-proteins consist of three tightly associated subunits, alpha, beta and gamma (1:1:1) in order of decreasing mass. Following agonist binding to the receptor, a conformational change is transmitted to the G-protein, which causes the G-alpha subunit to exchange a bound GDP for GTP and to dissociate from the beta and gamma subunits. The GTP-bound form of the alpha 15 subunit is typically the effector-modulating moiety. Signal amplification results from the ability of a single receptor to activate many G-protein molecules, and from the stimulation by G-alpha-GTP of many catalytic cycles of the effector.

Most opioid receptor-mediated functions appear to be mediated through G-protein interactions. Standifer and Pasternak (1997) Cell Signal. 9:237. Antisense 20 oligodeoxynucleotides directed against various G-protein alpha subunits were shown to differentially block the analgesic actions of the mu-, delta-, and kappa- opioid agonists in mice. Standifer et al. (1996) Mol. Pharmacol. 50:293.

The amino acid sequences of the opioid receptors are approximately 65% identical, and they have little sequence similarity to other G-protein-coupled receptors except for somatostatin. 25 Reisine and Bell (1993) Trends Neurosci. 16:506. The regions of highest similarity in sequence are the sequences predicted to lie in the seven transmembrane-spanning regions and the intracellular loops. Regions of amino acid sequence divergence are the amino and carboxy termini and the second and third extracellular loops.

Each receptor subtype has a characteristic pattern of expression. Mu-opioid receptor 30 mRNA is present in the periaqueductal gray, spinal trigeminal nucleus, cuneate and gracile nuclei, and thalamus regions of the brain involved in pain perception and associated with

morphine analgesia. Defts et al. (1994) J. Comp. Neurol. 345:46. It is also present in nuclei involved in control of respiration, consistent with the ability of morphine to depress respiration, and in neurons of the area postrema, where morphine has been shown to cause nausea and induce vomiting. Other consequences of mu-opioid receptor activation include miosis, reduced 5 gastrointestinal motility, and feelings of well-being or euphoria. Pasternak (1993). The pattern of mu-opioid receptor mRNA expression correlates with the brain centers involved in mediating the biological actions of morphine and mu-selective agonists. Delta-opioid receptor mRNA is found in the dorsal horn of the spinal cord. Kappa₁-opioid receptor mRNA is expressed in the hypothalamic regions, which may account for many of the neuroendocrine effects of the kappa 10 selective agonists.

Soon after the mu-opioid receptor MOR-1 was cloned (Chen et al. (1993); and Wang et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:10230), antisense experiments confirmed its involvement with morphine analgesia. Rossi et al. (1994) Life Sci. 54:375; and Rossi et al. (1995) FEBS Lett. 369:192. Antisense oligonucleotides directed against MOR-1 mRNA blocked 15 the analgesic actions of morphine in rats, demonstrating that proper translation of the MOR-1 mRNA was essential for modulating morphine analgesia. Antisense approaches have also demonstrated a relationship between MOR-1 activity and ingestive responses. Administration of antisense oligonucleotides directed against MOR-1 mRNA significantly reduced food and water intake and subsequently, body weight in rats.

20 In recent years, a number of mu-opioid receptor subtypes have been proposed. The first suggestion of mu₁ and mu₂ receptor subtypes came from a combination of binding and pharmacological studies based on the antagonists naloxonazine and naloxazone. Wolozin and Pasternak (1981) Proc. Natl. Acad. Sci. U.S.A. 78:6181; Reisine and Pasternak (1996); and Pasternak (1993). A gene encoding a mu receptor, MOR-1, has been identified. Min et al. 25 (1994) Proc. Natl. Acad. Sci. U.S.A. 91:9081; Giros et al. (1995) Life Sci. 56:PL369; and Liang et al. (1995) Brain Res. 679:82. The MOR-1 cDNA consists of exons 1-4, which total 1610 bp in length and encode 398 amino acids. More recently, pharmacological and molecular differences between morphine and morphine-6β-glucuronide (M6G) have suggested yet another mu-opioid receptor subtype. Pasternak and Standifer (1995) Trends Pharmacol. Sci. 16:344; 30 Rossi et al. (1995); and Rossi et al. (1996) Neurosci. Lett. 216:1.

Antisense oligonucleotides directed against selected exons within the MOR-1 mRNA revealed interesting therapeutic patterns of morphine and M6G analgesia, with some MOR-1 exons implicated in the analgesic actions of one drug, but not the other. Rossi et al. (1997) J. Pharmacol. Exp. Ther. 281:109; and Rossi et al. (1995). Although the two analgesics were 5 known to act through different receptors, the sensitivity of the effect of both analgesics to at least six different MOR-1 antisense probes implied that both receptors were closely associated with MOR-1, raising the possibility of pharmacologically relevant MOR-1 splice variants. Pasternak and Standifer (1995); and Rossi et al. (1995). Alternative splicing has been observed with a number of G-protein-coupled receptors, including somatostatin 2 (Vanetti et al. (1998) FEBS 10 Lett. 311:290), dopamine D2 (Guiramand et al. (1995) J. Biol. Chem. 270:7354), prostaglandin EP3 (Namba et al. (1993) Trends Pharmacol. Sci. 16:246), serotonin receptor subtypes 5-HT₄ and 5-HT₇ (Lucas and Hen. (1995) Trends Pharmacol. Sci. 16:246) and MOR-1 (Bare et al. (1994) FEBS Lett. 354:213; and Zimprich et al. (1995) FEBS Lett. 359:142).

Several opioid receptor splice variants have been identified and characterized. At least 15 two MOR-1 splice variants are known, the human MOR-1A and the rat MOR-1B. Bare et al. (1994); and Zimprich et al. (1995). The hMOR-1A splice variant consists of exons 1, 2, 3 and a new exon 3a, and was determined to possess ligand binding characteristics similar to the full-length MOR-1. Bare et al. (1994). The rMOR-1B splice variant consists of exons 1, 2, 3 and a new exon 5, and like hMOR-1A, differs from MOR-1 only in length and amino acid composition 20 at the carboxy-terminal tail. Zimprich et al. (1995). MOR-1B has affinity to opioid compounds similar to that of MOR-1, but is much more resistant to agonist-induced desensitization than MOR-1. The C-terminal differences between MOR-1 and MOR-1A or MOR-1B could have effects on receptor coupling or receptor transport and localization. About twenty splice variants 25 of the mouse MOR-1 gene (comprised of nine exons) have been identified and characterized. (see, e.g., PCT/US99/15974, published as WO 00/04046 and PCT/US02/20665, published as WO 03/002718 A2). The MOR-1 splice variants are potential targets for the modulation of physiological effects resulting from mu-opioid receptor activity. In addition, five splice variants 30 of the kappa3-related opioid receptor (i.e., opioid receptor-like receptor (ORL-1), OFQ receptor or nociceptin receptor) have been identified and characterized, suggesting an analogous system of modulation to that of the mu class of receptors. (PCT/US99/15977, published as WO 00/04151). Splice variants that were under control of two distinct promoters in the mouse *Oprm*

gene have been reported (see, e.g., Pan et al. (1999) Molecular Pharmacology 56, 396-403, Pan et al. (2000) FEBS Letters 466, 337-340, Pan et al. (2002) Gene 295, 97-108 and Pan et al. (2001) Proc.Natl.Acad.Sci.U.S.A 98, 14084-14089). Two additional human MOR-1 splice variants, hMOR-1O and hMOR-1X (see, e.g., Pan et al. (2003) Biochem Biophys Res Commun. 5 301, 1057-1061), have also been identified.

Availability of polynucleotide sequences of opioid receptor splice variants, and, in the case of splice variants in coding regions, the corresponding polypeptide sequences, will significantly increase the capability to design pharmaceutical compositions, such as analgesics, with enhanced specificity of function. In general, the availability of these polynucleotide and 10 polypeptide sequences will enable efficient screening of candidate compositions. The principle in operation through the screening process is straightforward: natural agonists and antagonists bind to cell-surface receptors and channels to produce physiological effects; certain other molecules can produce physiological effects and act as therapeutic pharmaceutical agents. Thus, the ability of candidate drugs to bind to opioid receptor splice variants can function as an 15 extremely effective screening criterion for the selection of pharmaceutical compositions with desired functional efficacy and specificity.

DISCLOSURE OF THE INVENTION

The invention encompasses MOR-1 splice variant polypeptides or polypeptide fragments or homologs thereof retaining MOR-1 activity.

20 The invention further encompasses a MOR-1 splice variant polynucleotide, encoding MOR-1 splice variant polypeptides or polypeptide fragments or homologs thereof retaining MOR-1 activity, and noncoding mRNA splice variants and complementary strands thereto.

25 The invention further encompasses a polynucleotide, or a complementary strand thereto that hybridizes under stringent conditions, comprising at least 15 consecutive nucleotides of an MOR-1 splice variant polynucleotide where the polynucleotide contains promoter elements.

30 The invention further encompasses methods of screening compositions for an opioid activity by obtaining a control cell that does not express a recombinant or endogenous opioid receptor, obtaining a test cell that expresses a recombinant MOR-1 splice variant polypeptide, contacting the control cell and test cell with an amount of an opioid sufficient to exert a physiologic effect, separately measuring the physiologic effect of the composition on the control cell and test cell and comparing the physiologic effect of the composition to the physiologic

effect of the opioid, where determination of a physiologic effect of the composition is expressed relative to that of the opioid.

The invention further encompasses methods of screening compositions for an opioid activity by obtaining a control polypeptide that is not a recombinant opioid receptor, obtaining a test polypeptide that is a recombinant MOR-1 splice variant polypeptide, contacting a composition with the control polypeptide and the test polypeptide, contacting the test polypeptide with an amount of an opioid sufficient to measurably bind the test polypeptide, measuring the binding of the composition and the opioid, and comparing the test polypeptide binding of the composition to that of the opioid, where determination of binding of the composition is expressed relative to that of the opioid.

The invention further encompasses methods of screening compositions for differential or selective opioid activity comprising obtaining a first and second test polypeptide that are MOR-1 splice variant polypeptide fragments and contacting each with a composition, measuring the binding affinity of the composition to the first and second test polypeptides and comparing the binding of the composition and the first test polypeptide to that of the second test polypeptide where differential activity is expressed as a ratio of the two binding affinities.

The invention further encompasses methods of screening compositions for a MOR-1 binding protein by obtaining a control cell that does not express a recombinant or endogenous opioid receptor, obtaining a test cell that expresses a recombinant MOR-1 splice variant polypeptide, contacting the control cell extract and test cell extract with the MOR-1 splice variant polypeptide and comparing the test cell extract binding to that of the control cell extract binding with the MOR-1 splice variant polypeptide of interest to identify a MOR-1 binding protein.

The invention further encompasses a method for regulating morphine analgesia in a subject by altering of MOR-1 splice variant polypeptide activity. Activity can be regulated by administering antigen binding fragments, agonists, antagonists, small molecule ligands, antisense nucleic acids or siRNA to a subject in an amount and for a duration sufficient to regulate morphine analgesia. The antigen binding fragment, agonist, antagonist, small molecule ligand, antisense nucleic acid or siRNA is directed to an MOR-1 splice variant polypeptide fragment or a homolog thereof or an MOR-1 splice variant mRNA. Morphine analgesia can also be regulated by homodimerization or homooligomerization among the MOR-1 splice variants and

heterodimerization or heterooligomerization between the variants and other opioid or non-opioid receptors.

The invention further encompasses regulating opioid activity by administering a DNA plasmid vector containing an MOR-1 splice variant polynucleotide. The DNA plasmid vector thereby expresses an mRNA splice variant that may encode an MOR-1 polypeptide in a subject in an amount of and duration sufficient to regulate morphine analgesia. Activity can also be regulated by administering an antisense nucleic acid or siRNA complementary to an MOR-1 splice variant polynucleotide, thereby blocking gene expression in a subject in an amount and duration sufficient to regulate morphine analgesia. Opioid activity can also be regulated by homodimerization or homooligomerization among the MOR-1 splice variants and heterodimerization or heterooligomerization between the variants and other opioid or non-opioid receptors.

The invention further encompasses antigen-binding fragments specific for the MOR-1 splice variant polypeptides described herein.

15 BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows the human mu opioid receptor gene structure and alternative splicing. Exons and introns are showed by boxes and horizontal lines, respectively.

FIG. 1B shows the partial cDNA sequences of the variants with translated amino acid sequences. The complete cDNA and deduced amino acid sequences of hMOR-1A, hMOR-1B1, hMOR-1B2, hMOR-1B3, hMOR-1B4, hMOR-1B5, and hMOR-1Y have been deposited in the GenBank database (Accession numbers: AY225404, AY309001, AY309005, AY309006, AY309007, AY309008, and AY309009). The cAMP- and cGMP-dependent protein kinase phosphorylation sites, caseine kinase II phosphorylation sites, tyrosine kinase phosphorylation site and translation stop codon are indicated by #, @, & and * respectively.

FIG. 2 shows a schematic of the protein structure for the human MOR-1 variants.

FIG. 3A depicts the nucleotide sequence and amino acid sequence of hMOR-1B1.

FIG. 3B depicts the nucleotide sequence and amino acid sequence of hMOR-1B2.

FIG. 3C depicts the nucleotide sequence and amino acid sequence of hMOR-1B3.

FIG. 3D depicts the nucleotide sequence and amino acid sequence of hMOR-1B4.

FIG. 3E depicts the nucleotide sequence and amino acid sequence of hMOR-1B5.

FIG. 3F depicts the nucleotide sequence and amino acid sequence of hMOR-1Y.

FIG. 4 shows an alignment of the human MOR-1 amino acid sequences.

FIG. 5 shows the partial cDNA sequences of the variants with translated amino acid sequences. The stop codons are indicated by *. The complete cDNA and deduced amino acid sequences of rMOR-1A, rMOR-1C1, rMOR-1C2, rMOR-1D, rMOR-1B2 and rMOR-1E have 5 been deposited in the GenBank database (Accession numbers. AY309000, AY225402, AY225403, AY309002, AY309003 and AY309004).

FIG. 6A depicts the nucleotide sequence and amino acid sequence of rMOR-1B2.

FIG. 6B depicts the nucleotide sequence and amino acid sequence of rMOR-1C1.

FIG. 6C depicts the nucleotide sequence and amino acid sequence of rMOR-1C2.

10 FIG. 6D depicts the nucleotide sequence and amino acid sequence of rMOR-1D.

FIG. 6E depicts the nucleotide sequence and amino acid sequence of rMOR-1E.

BEST MODE FOR CARRYING OUT THE INVENTION

In view of the strong pharmacological evidence for distinct mu-opioid receptors, alternative splicing of the MOR-1 gene has been explored further. It has now been determined 15 that the MOR-1 gene is subject to alternative splicing that produces novel splice variant forms of the mRNA and/or receptor. New exons for the MOR-1 gene have been identified, which combine to yield novel MOR-1 splice variant polynucleotides. These splice variant polynucleotides and the polypeptides encoded thereby are potential targets for modulating morphine analgesia and opioid-mediated ingestive responses.

20 The invention further encompasses isolated MOR-1 splice variant polynucleotides having the sequences of SEQ ID NOS: 50, 52, 54, 56, 58 or 60. In addition to SEQ ID NOS 50, 52, 54, 56, 58 or 60, the polynucleotide sequences can be any sequence of the appropriate genetic code to encode any of the MOR-1 splice variant polypeptides having the sequence of SEQ ID NOS: 51, 53, 55, 57, 59 or 61. Preferably, the polynucleotide is at least 15 consecutive nucleotides.

25 The invention further encompasses isolated MOR-1 splice variant polynucleotides having the sequences of SEQ ID NOS: 79, 81, 83, 85 or 87. In addition to SEQ ID NOS 79, 81, 83, 85 or 87, the polynucleotide sequences can be any sequence of the appropriate genetic code to encode any of the MOR-1 splice variant polypeptides having the sequence of SEQ ID NOS: 80, 82, 84, 86 or 88. Preferably, the polynucleotide is at least 15 consecutive nucleotides.

30 A “polynucleotide” is a polymeric form of nucleotides of any length, which contain deoxyribonucleotides, ribonucleotides, and analogs in any combination. Polynucleotides may

have three-dimensional structure, and may perform any function, known or unknown. The term “polynucleotide” includes double-, single-stranded, and triple-helical molecules. Unless otherwise specified or required, any embodiment of the invention described herein that is a polynucleotide encompasses both the double stranded form and each of two complementary forms known or predicted to make up the double stranded form of either the DNA, RNA or hybrid molecule.

The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as fluororibose and thiolate, and nucleotide branches. The sequence of nucleotides may be further modified after polymerization, such as by conjugation, with a labeling component. Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides or solid support.

An “isolated” polynucleotide or polypeptide is one that is substantially free of the materials with which it is associated in its native environment. By substantially free, is meant at least 50%, preferably at least 70%, more preferably at least 80%, and even more preferably at least 90% free of these materials.

The invention further comprises a complementary strand to the MOR-1 splice variant polynucleotide.

The complementary strand can be polymeric and of any length, and can contain deoxyribonucleotides, ribonucleotides, and analogs in any combination.

Hybridization reactions can be performed under conditions of different “stringency.” Conditions that increase stringency of a hybridization reaction are well known. See for examples, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook et al. 1989). Examples of relevant conditions include (in order of increasing stringency): incubation temperatures of 25°C, 37°C, 50°C, and 68°C; buffer concentrations of 10 x SSC, 6 x SSC, 1 x SSC, 0.1 x SSC (where SSC is 0.15 M NaCl and 15 mM citrate buffer) and their equivalent

using other buffer systems; formamide concentrations of 0%, 25%, 50%, and 75%; incubation times from 5 minutes to 24 hours; 1, 2 or more washing steps; wash incubation times of 1, 2, or 15 minutes; and wash solutions of 6 x SSC, 1 x SSC, 0.1 x SSC, or deionized water.

The invention further encompasses polynucleotides encoding functionally equivalent variants and derivatives of the MOR-1 splice variant polypeptides and functionally equivalent fragments thereof which may enhance, decrease or not significantly affect properties of the polypeptides encoded thereby. These functionally equivalent variants, derivatives, and fragments display the ability to retain MOR-1 activity. For instance, changes in a DNA sequence that do not change the encoded amino acid sequence, as well as those that result in conservative substitutions of amino acid residues, one or a few amino acid deletions or additions, and substitution of amino acid residues by amino acid analogs are those which will not significantly affect properties of the encoded polypeptide. Conservative amino acid substitutions are glycine/alanine; valine/isoleucine/leucine; asparagine/glutamine; aspartic acid/glutamic acid; serine/threonine/methionine; lysine/arginine; and phenylalanine/tyrosine/tryptophan.

The invention further encompasses the MOR-1 splice variant polynucleotides contained in a vector molecule or an expression vector and operably linked to a promoter element if necessary.

A “vector” refers to a recombinant DNA or RNA plasmid or virus that comprises a heterologous polynucleotide to be delivered to a target cell, either *in vitro* or *in vivo*. The heterologous polynucleotide may comprise a sequence of interest for purposes of therapy, and may optionally be in the form of an expression cassette. As used herein, a vector need not be capable of replication in the ultimate target cell or subject. The term includes cloning vectors for translation of a polynucleotide encoding sequence. Also included are viral vectors.

The term “recombinant” means a polynucleotide of genomic cDNA, semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in an arrangement not found in nature.

“Heterologous” means derived from a genetically distinct entity from the rest of the entity to which it is being compared. For example, a polynucleotide, may be placed by genetic engineering techniques into a plasmid or vector derived from a different source, and is a heterologous polynucleotide. A promoter removed from its native coding sequence and

operatively linked to a coding sequence other than the native sequence is a heterologous promoter.

The polynucleotides of the invention may comprise additional sequences, such as additional encoding sequences within the same transcription unit, controlling elements such as 5 promoters, ribosome binding sites, polyadenylation sites, additional transcription units under control of the same or a different promoter, sequences that permit cloning, expression, homologous recombination, and transformation of a host cell, and any such construct as may be desirable to provide embodiments of this invention.

A "host cell" denotes a prokaryotic or eukaryotic cell that has been genetically altered, or 10 is capable of being genetically altered by administration of an exogenous polynucleotide, such as a recombinant plasmid or vector. When referring to genetically altered cells, the term refers both to the originally altered cell and to the progeny thereof.

Polynucleotides comprising a desired sequence can be inserted into a suitable cloning or expression vector, and the vector in turn can be introduced into a suitable host cell for replication 15 and amplification. Polynucleotides can be introduced into host cells by any means known in the art. The vectors containing the polynucleotides of interest can be introduced into the host cell by any of a number of appropriate means, including direct uptake, endocytosis, transfection, f-mating, electroporation, transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; and 20 infection (where the vector is infectious, for instance, a retroviral vector). The choice of introducing vectors or polynucleotides will often depend on features of the host cell.

Once introduced, the exogenous polynucleotide can be maintained within the cell as a non-integrated vector (such as a plasmid) or integrated into the host cell genome. Amplified DNA can be isolated from the host cell by standard methods. See, e.g., Sambrook et al. (1989). 25 RNA can also be obtained from transformed host cell, or it can be obtained directly from the DNA by using a DNA-dependent RNA polymerase.

Expression vectors generally are replicable polynucleotide constructs that contain a polynucleotide encoding the polypeptide of interest. Herein, this means any of the MOR-1 splice variant polypeptides. For expression, one or more translational controlling elements are also 30 usually required, such as ribosome binding sites, translation initiation sites and stop codons. These controlling elements (transcriptional and translational) can be derived from the MOR-1

gene, or heterologous (i.e., derived from other genes or other organisms). A number of expression vectors suitable for expression in eukaryotic cells including yeast, avian, and mammalian cells are well known in the art. One example of an expression vector is pcDNA3 (Invitrogen, San Diego, CA), in which transcription is driven by the cytomegalovirus (CMV) early promoter/enhancer. This vector also contains recognition sites for multiple restriction enzymes for insertion of an MOR-1 splice variant polypeptide of interest. Another example of an expression vector system is the baculovirus/insect system.

Cloning and expression vectors typically contain a selectable marker (for example, a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector), although such a marker gene can be carried on another polynucleotide sequence co-introduced into the host cell. Only those host cells into which a selectable gene has been introduced will grow under selective conditions. Typical selection genes either: (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate; (b) complement auxotrophic deficiencies; or (c) supply critical nutrients not available for complex media. The choice of the proper marker gene will depend on the host cell, and appropriate genes for different hosts are known in the art. Vectors also typically contain a replication system recognized by the host.

Suitable cloning vectors can be constructed according to standard techniques, or selected from a large number of cloning vectors available in the art. While the cloning vector selected may vary according to the host cell intended to be used, useful cloning vectors will generally have the ability to self-replicate, may possess a single target for a particular restriction endonuclease, or may carry marker genes. Suitable examples include plasmids and bacterial viruses, e.g., pUC18, mp18, mp19, pBR322, pMB9, ColE1, pCR1, RP4, phage DNAs, and shuttle vectors such as pSA3 and pAT28. These and other cloning vectors are available from commercial vendors such as BioRad, Stratagene, and Invitrogen.

According to an embodiment of the invention, the vectors, e.g., *in vivo* expression vectors, are viral vectors. Viral vectors, e.g., viral expression vectors are advantageously: poxviruses, e.g. vaccinia virus or an attenuated vaccinia virus. When the expression vector is a vaccinia virus, insertion site or sites for the polynucleotide or polynucleotides to be expressed are advantageously at the thymidine kinase (TK) gene or insertion site, the hemagglutinin (HA) gene or insertion site, the region encoding the inclusion body of the A type (ATI); see also documents

cited herein, especially those pertaining to vaccinia virus. The insertion site or sites for MVA virus area advantageously as in various publications, including Carroll M. W. et al., Vaccine, 1997, 15 (4), 387-394; Stittelaar K. J. et al., J. Virol., 2000, 74 (9), 4236-4243; Sutter G. et al., 1994, Vaccine, 12 (11), 1032-1040; and, in this regard it is also noted that the complete MVA 5 genome is described in Antoine G., Virology, 1998, 244, 365-396, which enables the skilled artisan to use other insertion sites or other promoters. When the expression vector is a poxvirus, the polynucleotide to be expressed is inserted under the control of a specific poxvirus promoter, e.g., the vaccinia promoter 7.5 kDa (Cochran et al., J. Virology, 1985, 54, 30-35), the vaccinia promoter I3L (Riviere et al., J. Virology, 1992, 66, 3424-3434), the vaccinia promoter HA 10 (Shida, Virology, 1986, 150, 451-457), the cowpox promoter ATI (Funahashi et al., J. Gen. Virol., 1988, 69, 35-47), the vaccinia promoter H6 (Taylor J. et al., Vaccine, 1988, 6, 504-508; Guo P. et al. J. Virol., 1989, 63, 4189-4198; Perkus M. et al., J. Virol., 1989, 63, 3829-3836), *inter alia*. When the expression vector is a herpes virus, the polynucleotide to be expressed is inserted under the control of a eukaryotic promoter, such as a strong eukaryote promoter, 15 15 advantageously a CMV-IE (murine or human) promoter; that is, in embodiments herein, the polynucleotide to be expressed is operably linked to a promoter, and in herpes virus embodiments, advantageously the polynucleotide to be expressed is operably linked to a strong eukaryotic promoter such as a mCMV-IE or hCMV-IE promoter.

The invention further encompasses an isolated polynucleotide, or a complementary strand 20 thereto that hybridizes under stringent conditions, comprising at least 15 consecutive nucleotides of the MOR-1 splice variant polynucleotides depicted in FIG. 2 where the polynucleotide contains promoter elements.

The MOR-1 splice variant promoter elements are contained in exons 1a, 1b, and 1c or in any combination thereof. Promoter elements can control the level, tissue specificity, inducibility 25 and, in gene clusters, the sequence of transcriptional activation and repression. Promoter elements include but are not limited to, enhancer sequences and repressor sequences.

The invention encompasses splice variant polypeptides. The exemplary MOR-1 splice variant polypeptides are composed of the amino acids indicated in FIGS. 3 and 6. Polypeptide fragments comprising 5 amino acids, more preferably 7 amino acids, more preferably 15 amino 30 acids, more preferably 25 amino acids, more preferably 50 amino acids and more preferably 75

amino acids, which are not the same as the known MOR-1 or MOR-1 variants are claimed herein and encompassed in the term "MOR-1 splice variant polypeptides".

The terms "protein", "peptide", "polypeptide" and "polypeptide fragment" are used interchangeably herein to refer to polymers of amino acid residues of any length. The polymer 5 can be linear or branched, it may comprise modified amino acids or amino acid analogs, and it may be interrupted by chemical moieties other than amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling or bioactive component.

10 The MOR-1 splice variant polypeptides retain MOR-1 activity. To "retain MOR-1 activity" is to have a similar level of functional activity as the MOR-1 polypeptide. This activity includes, but is not limited to, immunologic and pharmacologic activity.

15 The "immunologic activity" is binding to anti-opioid receptor antigen binding fragments. The antigen binding fragments can be any functional antibody, fragment or derivative thereof, including, but not limited to, whole native antibodies, bispecific antibodies, chimeric antibodies, Fab, F(ab')2, single chain V region fragments (scFv), and fusion polypeptides comprising an 20 antigen binding fragment fused to a chemically functional moiety.

The "pharmacologic activity" is activation or deactivation of the MOR-1 splice variant polypeptides upon binding of agonists or antagonists.

25 The invention further encompasses MOR-1 splice variant polypeptide homologs. A "homolog" is a polypeptide similar in amino acid sequence to other polypeptides among a single species or, a "homolog" in evolution is a polypeptide similar in amino acid sequence to other polypeptides in different species because they have been inherited from a common ancestor. Preferably, homologs of the present invention are human homologs.

30 Isolation of MOR-1 splice variant human homolog cDNAs can be carried out by any method known in the art. For instance, methods analogous to the isolation of the human and rat MOR-1 splice variants described herein (see Examples 1 and 2). Using primers corresponding to the human MOR-1 gene and a Marathon-Ready human cDNA Library to carry out reactions according to the Marathon cDNA Amplification Kit (Clontech), human MOR-1 splice variants can be obtained. Alternatively, screening of human cDNA libraries with probes corresponding

to mouse MOR-1 splice variant sequences can be carried out at reduced stringency to identify human MOR-1 splice variant cDNAs.

The invention further encompasses the MOR-1 splice variant polypeptides in a heterodimeric or homodimeric form. A “heterodimer” is a protein made up of more than one kind of polypeptide. A “homodimer” is a protein made up of more than one kind of polypeptide.

Pharmaceutical compositions and treatment modalities can be detected by the methods of this invention. The MOR-1 splice variant polypeptide fragments and MOR-1 splice variant nucleic acid sequences can be used in screening for compositions that alter variant activity. Compositions that selectively regulate the MOR-1 splice variant polypeptide fragments or 10 selectively modulate physiological processes can be identified.

The invention further encompasses methods of screening compositions for opioid activity by obtaining a control cell that does not express a recombinant opioid receptor and obtaining a test cell that is the same as the control cell except that it expresses a recombinant MOR-1 splice variant polypeptide, contacting the control cell and test cell with an amount of an opioid 15 sufficient to exert a physiologic effect, separately measuring the physiologic effect of the composition on the control cell and test cell and comparing the physiologic effect of the composition to the physiologic effect of the opioid, where determination of a physiologic effect of the composition is expressed relative to that of the opioid.

The invention further comprises a method of screening compositions for opioid activity 20 by obtaining a control polypeptide that is not a recombinant opioid receptor and obtaining a test polypeptide that is a recombinant MOR-1 splice variant polypeptide, contacting a composition with the control polypeptide and the test polypeptide, contacting the test polypeptide with an amount of an opioid sufficient to measurably bind the test polypeptide, measuring the binding of the composition and the opioid and comparing the test polypeptide binding of the composition to 25 that of the opioid, where determination of binding of the composition is expressed relative to that of the opioid.

The invention further encompasses a method of screening compositions for differential opioid activity by obtaining a first test polypeptide that is an MOR-1 splice variant polypeptide and contacting it with a composition and obtaining a second test polypeptide that is an MOR-1 30 splice variant polypeptide, measuring the binding of the composition to the first and second test polypeptides, and comparing the binding of the composition and the first test polypeptide to that

of the second test polypeptide where differential activity is expressed as a ratio of the two binding affinities.

The invention further encompasses methods of screening compositions for a MOR-1 binding protein by obtaining a control cell that does not express a recombinant or endogenous opioid receptor, obtaining a test cell that expresses a recombinant MOR-1 splice variant polypeptide, contacting the control cell extract and test cell extract with the MOR-1 splice variant polypeptide and comparing the test cell extract binding to that of the control cell extract binding with the MOR-1 splice variant polypeptide of interest to identify a MOR-1 binding protein. For example, but not by limitation, the MOR-1 binding protein can be identified by two hybrid screen, which is known to one of skill in the art (see, e.g., U.S. Patent Nos. 5,525,490; 5,948,620; 5,955,280; 5,965,368; 6,051,381; 6,251,676; 6,479,289 and 6,562,576).

The compositions screened include, but are not limited to, chemical, synthetic combinatorial libraries of small molecule ligands, eukaryotic whole cell lysates or extracts, media conditioned by cultured eukaryotic cells, natural products and extracts thereof.

The opioid can be, but is not limited to, morphine, methadone, etorphine, levorphanol, fentanyl, sufentanil, [D-Ala², MePhe⁴, Gly(ol)⁵]enkephalin (DAMGO), pentazocine, ethylketocyclazocine, bremazocine, spiradoline, [D-Ser², Leu⁵]enkephalin-Thr⁶ (DSLET), Met-enkephalin, Leu-enkephalin, β-endorphin, dynorphin A, dynorphin B, α-neoendorphin analogs and combinatorial chemistry products thereof.

The physiological effect can be measured by any method known in the art such as changes in the levels of neuroendocrine hormones, including, but not limited to prolactin, growth hormone, gonadotropin-releasing hormone, adrenocorticotropin, corticotropin-releasing factor, luteinizing hormone, follicle stimulating hormone, testosterone or cortisol. The physiological effect can also be measured by changes in the levels of neurotransmitters, including but not limited to, acetylcholine or dopamine.

Activation of an MOR-1 receptor, and likely, the MOR-1 splice variant polypeptides, stimulates a variety of physiological responses, including analgesia, depression of gastrointestinal motility and respiration, and alterations of the immune, endocrine and autonomic nervous system. Compositions that regulate the activity of the MOR-1 receptor and/or the MOR-1 splice variant polypeptides can elicit responses that have therapeutic effects. The invention is useful in diagnosis, treatment, design and screening of novel reagents. Screening of

compounds can result in obtaining those with differential or selective activity. That is, for instance, certain compositions can retain analgesic effects but do not affect peristaltic activity and thus do not cause constipation. Conversely, compositions that lack analgesic effects but affect peristaltic activity would be useful in treating chemotherapy and HIV patients. Other 5 applications relating to the side effects of opiates can be readily envisaged by one of skill in the art.

The invention further encompasses a method for regulating morphine analgesia in a subject by altering the amount of MOR-1 splice variant polypeptide activity in the subject. Activity can be regulated by administering antigen binding fragments, agonists, antagonists or 10 small molecule ligands to a subject in an amount and duration sufficient to regulate morphine analgesia. The antigen binding fragment, agonist, antagonist or small molecule ligand is directed to an MOR-1 splice variant. Activity can also be regulated by homodimerization or homooligomerization among the MOR-1 splice variants and heterodimerization or heterooligomerization between the variants and other opioid or non-opioid receptors.

15 Activity can also be regulated by administering a DNA plasmid vector containing an MOR-1 splice variant polynucleotide. The DNA plasmid vector thereby expresses an MOR-1 splice variant polynucleotide in a subject in an amount and a duration sufficient to regulate morphine analgesia. Activity can also be regulated by administering an antisense nucleic acid or siRNA complementary to an MOR-1 splice variant polynucleotide, thereby blocking gene 20 expression in a subject in an amount and a duration sufficient to regulate morphine analgesia. Methods for administering antisense and siRNA are known to one of skill in the art (reviewed in Brantl, Biochim Biophys Acta. 2002 May 3;1575(1-3):15-25 and Lavery & King, Curr Opin Drug Discov Devel. 2003 Jul;6(4):561-9).

Agonists and antagonists of MOR-1 splice variant polypeptide activity can include but 25 are not limited to, morphine, methadone, etorphine, levorphanol, fentanyl, sufentanil, [D-Ala², MePhe⁴, Gly(ol)5]enkephalin (DAMGO), butorphanol, naloxone, naltrexone, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH₂ (CTOP), diprenorphine, β-funaltrexamine, naloxonazine, nalorphine, pentazocine, nalbuphine, benzoylhydrazone, bremazocine, ethylketocyclazocine, trans-(−)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (also known as U50488), 30 (5-alpha,7-alpha,8-beta)-(+)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl]-benzeneacetamide (also known as U69593), spiradoline, naltrindole, [D-Pen², D-Pen-

⁵]enkephalin (DPDPE), [D-Ala²,Glu⁴]deltorphin, [D-Ser²,Leu⁵]enkephalin-Thr⁶ (DSLET), Met-enkephalin, Leu-enkephalin, β-endorphin, dynorphin A, dynorphin B, α-neoendorphin and derivatives such as those produced by combinatorial chemistry and their mixtures and physiologically acceptable salts thereof.

5 A “subject” is a vertebrate, preferably a mammal, and more preferably a human.

Mammals include but are not limited to humans, farm animals, sport animals, and pets.

The invention further encompasses antigen binding fragments specific for an MOR-1 splice variant polypeptide. According to the invention, an MOR-1 splice variant polypeptide can be used as an immunogen to generate antigen-binding fragments which immunospecifically bind 10 the immunogen.

Production of antigen binding fragments such as polyclonal antibodies can be carried out by any method known in the art. Various host animals can be immunized by injection with the immunogen, including but not limited to rabbits, mice and rats. Various adjuvants can be used to increase the immunological response, depending on the host species, and including but not 15 limited to Freund's (complete or incomplete) adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (Bacille Calmette-Guerin) and Corynebacterium parvum.

For preparation of antigen binding fragments such as monoclonal antibodies, any 20 technique that provides for the production of antibody molecules by continuous cell lines in culture can be used. Examples of such techniques include the original hybridoma technique (Kohler and Milstein (1975) Nature 256:495) as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al. (1983) Immunol. Today 4:72), and the EBV hybridoma technique to produce human monoclonal antibodies. Cole et al. (1985) in Monoclonal 25 Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96. Monoclonal antibodies can also be produced in germ-free animals utilizing known technology. PCT/US90/02545. Human antibodies can be obtained using human hybridomas (Cote et al. (1983) Proc. Natl. Acad. Sci. U.S.A. 80:2026), or by transforming human B cells with EBV virus in vitro. Cole et al. (1985). Techniques developed for the production of “chimeric antibodies” by splicing the genes from a 30 mouse antibody molecule specific for MOR-1 splice variants together with genes from a human antibody of appropriate biological activity can be used. Morrison et al. (1984) Proc. Natl. Acad.

Sci. U.S.A. 81:6851; Neuberger et al. (1984) Nature 312:604; and Takeda et al. (1985) Nature 314:452.

Techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce MOR-1 splice variant polypeptide-specific single chain antibodies. Techniques described for the production of Fab expression libraries (Huse et al. (1989) Science 246:1275) can be utilized, allowing rapid and easy identification of monoclonal Fab fragments specific for an MOR-1 splice variant polypeptide.

Antibody fragments that contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab), fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(abl) fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments.

Single chain V region fragments (“scFv”) can also be produced. Single chain V region fragments are made by linking L (light) and/or H (heavy) chain V (variable) regions by using a short linking peptide. Bird et al. (1988) Science 242:423. Any peptide having sufficient flexibility and length can be used as a linker in a scFv. Usually the linker is selected to have little to no immunogenicity. An example of a linking peptide is (GGGGS)₃, which bridges approximately 3.5 nm between the carboxy terminus of one V region and the amino terminus of another V region. Other linker sequences can also be used, and can provide additional functions, such as for attaching a drug or a solid support.

All or any portion of the H or L chain can be used in any combination. Typically, the entire V regions are included in the scFv. For instance, the L chain V region can be linked to the H chain V region. Alternatively, a portion of the L chain V region can be linked to the H chain V region or a portion thereof. Also contemplated are scFvs in which the H chain V region is from H11, and the L chain V region is from another immunoglobulin. It is also possible to construct a biphasic, scFv in which one component is an MOR-1 splice variant polypeptide and another component is a different polypeptide, such as a T cell epitope.

The scFvs can be assembled in any order, for example, V_H—(linker)—V_L or V_L—(linker)—V_H. There may be a difference in the level of expression of these two configurations in particular expression systems, in which case one of these forms may be

preferred. Tandem scFvs can also be made, such as (X)—(linker)—(X)—(linker)—(X), in which X are MOR-1 splice variant polypeptides, or combinations of MOR-1 splice variant polypeptides with other polypeptides. In another embodiment, single chain antibody polypeptides have no linker polypeptide, or just a short, inflexible linker. Exemplary configurations include $V_L—V_H$ and $V_H—V_L$. The linkage is too short to permit interaction between V_L and V_H within the chain, and the chains form homodimers with a V_L/V_H antigen-binding site at each end. Such molecules are referred to in the art as “diabodies”.

ScFvs can be produced either recombinantly or synthetically. For synthetic production of scFv, an automated synthesizer can be used. For recombinant production of scFv, a suitable plasmid containing a polynucleotide that encodes the scFv can be introduced into a suitable host cell, either eukaryotic, such as yeast, plant, insect or mammalian cells, or prokaryotic, such as *Escherichia coli*, and the protein expressed by the polynucleotide can be isolated using standard protein purification techniques.

A particularly useful system for the production of scFvs is plasmid pET-22b(+) (Novagen, Madison, WI) in *E. coli*. pET-22b(+) contains a nickel ion binding domain consisting of 6 sequential histidine residues, which allows the expressed protein to be purified on a suitable affinity resin. Another example of a suitable vector is pcDNA3 (Invitrogen, San Diego, CA), described above.

The following examples are provided to illustrate but not limit the claimed invention. The examples demonstrate isolation and characterization of MOR-1 splice variants, and are representative of the methods employed for all claimed MOR-1 splice variants.

EXAMPLE 1: Identification and characterization of six new alternatively spliced variants from the human mu opioid receptor gene, *Oprm*

The mu opioid receptor plays an important role in mediating the actions of morphine and morphine-like drugs. Binding and pharmacological studies have proposed several mu receptor 5 subtypes, but only one mu opioid receptor (*Oprm*) gene has been isolated. The Examples herein describe the identification and characterizion of six new splice variants from the human *Oprm* gene using an RT-PCR strategy. The variants display differences on their carboxyl termini resulting from alternative splicing of the fourth exon. Northern blot analysis demonstrated expression of the variant mRNAs. Receptor binding assays established that these variants 10 belonged to the mu opioid receptor family with limited differences in opioid ligand affinities. However, adenylyl cyclase assays revealed significant differences in both opiate potency and efficacy among these variants. Dissociation between binding affinity and efficacy/potency among these variants might provide important insights to understanding the varied opioid responses observed clinically, and into designing new selective drugs based upon these 15 differences in efficacy/potency.

Primer design. In order to identify potential mouse homologs containing exons 5 in the human *Oprm* gene, a sequence alignment was performed among a ~ 7.7 kb mouse genomic sequence containing exons 5a, 5b, 5c, 5d and 5e, a ~ 7.3 kb rat and a ~ 8 kb human corresponding genomic sequences obtained from Public human genome databases (NCBI and 20 Ensembl), with Vector NTI software (Informatix). Three sets of antisense primers were designed. One of the primers (primer A) was derived from the human exon 5a that was highly homologous to the mouse or rat exon 5a, while the other two sets of primers (primers B and C) were from the regions homologous to the mouse exons 5c and 5d, respectively.

Reverse transcription-polymerase chain reaction (RT-PCR) cloning. Total RNA was 25 extracted from Be(2)C, a human neuroblastoma cell line, with the guanidinium thiocyanate phenol-chloroform extraction method (see, e.g., Pan et al. (1995) Molecular Pharmacology 47, 1180-1188), and reverse transcribed with primer A (5'-GCT TCC AAT CTT ATA TTC TTT CAC GG-3', SEQ ID NO:1) and Superscript II reverse transcriptase (Invitrogen) as previously described. The first-strand cDNA was then used as a template in PCRs with a sense primer A1 30 from the 5' untranslated region of exon 1 (5'-GAA AGG AAG CGG CTG AGG CGC T-3', SEQ ID NO:2) and the antisense primer A from exon 5a, or the antisense primer B1 from exon 5c (5'-

GTG TAT TGT CTA TTA GAG TGA GGC TAA CAT TTC TTT GG-3', SEQ ID NO:3), or the antisense primer C1 from exon 5d (5'-CCA CAC GGC AGT ACC TTC TCT TGG TCT CC-3', SEQ ID NO:4). Having no visible bands by the first-round PCR, nested PCRs were followed by using the first-round PCR products as templates and nested primers including a sense primer A2
5 (5'-CGG TGC TCC TGG CTA CCT CGC A-3', SEQ ID NO:5) and the antisense primer A, or the antisense primer B2 (5'-GGT TAG ATG GCT TTT ATC ATC ATA TTG CTG G-3', SEQ ID NO:6), or the antisense primer C2 (5'-GGG AAC AGG AAT TTT AGG GTT CAT GTCATA G-3', SEQ ID NO:7). Six cDNA fragments arranging from ~1.2 to 2.6 kb in size were obtained, subcloned into pCRII-TOPO vector (Invitrogen), and sequenced in both strands.
10 Sequence analysis of the cDNAs showed that all the clones had the same exons 1, 2 and 3 as the original hMOR-1, but contained an alternative fourth exon that was resulted from combination of six different exons (exons 5a, 5b, 5c, 5d, 5e and Y generated by using different splice site within exon 5 and a novel exon, exon Y). The corresponding variants were named as hMOR-1B1, hMOR-B2, hMOR-1B3, hMOR-1B4, hMOR-1B5 and hMOR-1Y, respectively. hMOR-1A was
15 amplified from the first-strand cDNA reverse-transcribed from Be(2)C RNA with random primers in a nested PCR using two sense primers (A1 & A2) from exon1 and two antisense primers (D1: 5'-GCT TCC CCT CTT CCC TCC ATT CTC-3', SEQ ID NO:8; D2: 5'-GGA TTA AAC TCC TAG TTT AGC ACA AAG CC-3', SEQ ID NO:9) from exon 3b sequence obtained from Public genome databases.

20 Northern blot analysis. Northern blot analysis was performed as described previously (see, e.g., Pan et al. (2001) Proc.Natl.Acad.Sci.U.S.A 98, 14084-14089). In brief, total RNA was isolated from Be(2)C cells (see above). 20 µg of total RNA per lane was loaded, separated on a 0.8% formaldehyde agarose gel, and transferred to a GenePlus membrane. The membrane was then hybridized with ³²P-labeled cDNA probes generated by PCR with appropriate primers. The
25 primers used were a sense primer (E: 5'-GCC ACC AGT ACC CTG CCC TTC C-3', SEQ ID NO:10) from exon 2 and an antisense primer (F: 5'-CTC AAT GTT GGA AGA GGT TGG GAT AC-3', SEQ ID NO:11) from exon 3 for a exons 2&3 probe, a sense primer (G: 5'-GTA CGC AGT CTC TAG AAT TAG GTA TAT CTA CTG-3', SEQ ID NO: 12) and an antisense primer (H: 5'-GGA TTC TAG ATC AGA ATT ATT TCT ATA ATG TGC-3', SEQ ID NO:13) from exon 3b for an exon 3b probe, a sense primer (I: 5'-GAG ACC ACC CCT CCA CGG C-3', SEQ ID NO: 14) from exon 3a and an antisense (J: 5'-GGT CTC CAT TAG GGC TAG CAG CAG-

3', SEQ ID NO:15) from exon 5a for na exon 5a probe, a sense primer (K: 5'-CAG AGA GAA AGA AGA CAG AAA TCT GAC TGG TAA G-3', SEQ ID NO:16) and an antisense primer (L: 5'-GAG AGC ACG TGT TGA AAC TGC AAG TCA GAG-3', SEQ ID NO:17) from exon 5b for an exon 5b probe, a sense primer (M: 5'-GGA CCT CCA GCC AAG TTT GTT GCT GAC-5', SEQ ID NO:18) and an antisense primer (N: 5'-CTC TCT GTG CAA ACG GTT GAA TGA ATG G-3', SEQ ID NO:19) from exon 5c for an exon 5c probe, a sense primer (O: 5'-CAG AGC TGA CTA TGA CAT GAA CCC TAA AAT TCC TG-3', SEQ ID NO:20) and an antisense primer (P: 5'-GGT CCC TGA AAC CAA CAA AAA AAC TGG ATG-3', SEQ ID NO: 21) from exon 5d for an exon 5d probe, a sense primer (Q: 5'-CAG GTG GAA TTG AAC CTG GAC TGT CAC TGT G-3', SEQ ID NO:22) and an antisense primer (S: 5'-GCT CTA AAA ATC ATA TGA AAT AGT TAC AAG CCT TTG-3', SEQ ID NO:23) from exon 5e for an exon 5e probe, and a sense primer (T: 5'-CAT CAG ATC AGA GAT CCA ATA TCA AAC CTT CCC-3', SEQ ID NO:24) and an antisense primer (U: 5'-GGA GGT CCC TTG ATA ACT GCC AAA TCG C-3', SEQ ID NO:25) from exon Y for an exon Y probe. The sizes of the probes were 728 bp for exons 2&3 probe, 319 bp for exon 3b probe, 184 bp for exon 5a probe in which a 47 bp sequence was from exon 3a, 309 bp for exon 5b probe, 272 bp for exon 5c probe, 145 bp for exon 5d probe, 156 bp for exon 5e probe, and 122 bp for exon Y probe, respectively. After washing, the membranes were exposed to Kodak BioMax MS film.

Expression of the variants in Chinese Hamster Ovary (CHO) cells. The cDNA fragments containing full-length variants including the original hMOR-1 in pCRII-TOPO were subcloned into pcDNA5FRT (Invitrogen) or pcDNA3 vector. A cDNA fragment containing only exons 1, 2 and 3 was also generated by PCR with the sense primer A2 from exon 1 (see above) and an antisense primer (V: 5'-GAT CTC GAG TCA TTA CTG ATG ATT AGT TCT ATC CAC TGT ATT GGC-3, SEQ ID NO:26) and subcloned into pcDNA5FRT. The resulting plasmids, hMOR-1/pcDNA5FRT, hMOR-1A/pcDNA5FRT, hMOR-1B1/pcDNA3, hMOR-1B2/pcDNA5FRT, hMOR-1B3/pcDNA5FRT, hMOR-1B4/pcDNA5FRT, hMOR-1B5/pcDNA5FRT, hMOR-1Y/pcDNA5FRT and hMOR-1(exons1-3)/pcDNA5FRT were transfected into CHO cells with or without pOG44 construct (Flip-In system, Invitrogen) by LipofectAMINE reagent (Invitrogen). Stable transformants were obtained 10 - 14 days after selection with hygromycin or G418 and screened with [³H]DAMGO binding assay.

Receptor Binding Assays. Membranes were prepared from stable transfectants as described previously (see, e.g., Pan et al. (1999) Molecular Pharmacology 56, 396-403). [³H]DAMGO saturation and competition binding assays were performed at 25°C for 60 minutes in 50mM potassium phosphate buffer, pH 7.4, containing 5mM magnesium sulfate. Specific binding was defined as the difference between total binding and nonspecific binding, determined in the presence of levallorphan (10 μM). K_D, Bmax and K_i values were calculated by nonlinear regression analysis (GraphPad Prism, Carlsbad, CA). Protein concentrations were determined as previously described using BSA as the standard (see, e.g., Lowry et al. (1951) Journal of Biological Chemistry 193, 265-275).

10 Adenylyl cyclase assay. Adenylyl cyclase activity in intact cells was determined as previously reported (Thakker et al. (2003) Methods Mol Med. 84, 29-37). Briefly, intact stable transfectant cells (0.07-0.18 mg of protein) were incubated in Hanks' balanced salt solution (137 mM NaCl, 5 mM KCl, 0.6 mM Na₂HPO₄, 0.4 mM KH₂PO₄, 4 mM NaHCO₃, 6 mM D-glucose, 0.5 mM MgCl₂, 0.4 mM MgSO₄, and 1 mM CaCl₂) containing 0.5 mM 3-isobutyl-1-methylxanthine for 5 min at 37°C. after adding forskolin (10 μM) and/or agonists (0.01nM - 10μM) on ice, cells were then incubated for 10 min at 37°C. The reaction was stopped by incubating the tubes in a boiling water bath for 6 min. The tubes were centrifuged for 5 min at 11,000g, and cAMP levels from the supernatant were then measured in a competition assay for [³H]cAMP binding. The supernatants were incubated with 0.8 pM [³H]cAMP in binding buffer 20 containing 25 mM Tris-HCl, pH 7.0, 10 mM theophylline, 0.1% BSA, , and 0.25 mg/ml adrenal cortex extract for 1 h at 4°C. After adding 75 μl of hydroxyapatite [50% (w/v)] and incubating for 6 min at 4°C to terminate the reaction, the reaction was then filtered through No. 34 glass-fiber filters (Schleicher & Schuell) and washed three times with 3 ml of ice-cold 10 mM Tris-HCl, pH 7.0 on a semiautomatic cell harvester. Filters were transferred into vials with 5 ml of Liquiscent (National Diagnostics, Atlanta, GA), and the radioactivity in vials were determined by scintillation spectroscopy in a Packard TRI-CAEB 2900TR counter. A parallel standard curve setting using unlabeled cAMP (0.4 – 125 pmol) was performed to calculate the cAMP level in the supernatants.

25 Cloning new splice variants from the human Oprm Gene. To isolate potential human MOR-1 variants homologous to those identified in mice, three sets of human antisense primers were designed based upon the genomic sequence alignment among mouse, rat and human, and

then used these antisense primers together with two sense primers from 5'UTR of exon 1 in an RT-PCR strategy. Six new variants were identified, hMOR-1B1, hMOR-1B2, hMOR-1B3, hMOR-1B4, hMOR-1B5 and hMOR-1Y, from Be(2)C, a human neuroblastoma cell line that expresses high level of mu opioid receptors (FIG. 1A). Sequence analysis revealed that all the 5 variants contained the same exons 1, 2 and 3 as the original MOR-1, but had a different fourth exon, which resembled splicing patterns similar to two earlier human (hMOR-1O and hMOR-1X) as well as eleven mouse (mMOR-1B1, mMOR-1B2, mMOR-1B3, mMOR-1B4, mMOR-1B5, mMOR-1C, mMOR-1D, mMOR-1E, mMOR-1F, mMOR-1O and mMOR-1P) variants (see, e.g., Pan et al. (2000) FEBS Letters 466, 337-340 and Suzuki et al. (1998) Life Sciences 64, 10 PL1-PL7). Therefore, all these variants contained the same protein structure on cell membrane, except with a different intracellular carboxyl terminus (FIG. 2). The common protein sequence includes all seven transmembrane domains and the binding pocket. Similar to the mouse variants associated with exons 5 (mMOR-1B1, mMOR-1B2, mMOR-1B3, mMOR-1B4 and mMOR-1B5), the human exon 5 variants were produced from alternative splicing within exon 5 15 and all the splice junctions contained consensus splicing sequences. However, the predicted amino acid sequences from the human variants differed from those from the mouse variants, and from each other due to sequence divergence (Figs. 1B and 2).

In hMOR-1B1, the first five of the total eighteen amino acids deduced from exon 5a were identical to those in mMOR-1B1 and rat MOR-1B. However, there was no termination codon 20 after the fifth amino acid as in mMOR-1B1 and rMOR-1B, and translation stopped after the eighteenth amino acid. Therefore, hMOR-1B1 contained an additional thirteen amino acids on its carboxyl terminal. Exons 5b, 5c, 5e and Y predicted 9, 15, 22 and 14 amino acids in hMOR-1B2, hMOR-1B3, hMOR-1B5 and hMOR-1Y, respectively, whereas exon 5d in hMOR-1B4 25 deduced only one amino acid, a serine residue, the shortest version of all carboxyl terminal variants cloned so far. Several potential protein kinase phosphorylation sites for cAMP- and cGMP-dependent protein kinase and tyrosin kinase were present in hMOR-1B1, hMOR-1B2 and hMOR-1Y, respectively (FIGS. 1B and 2).

Northern blot analysis of human MOR-1 variant mRNA. Northern blot analysis was performed to estimate the relative size and abundance of the variant mRNAs. Since all the 30 variants contained exons 1, 2 and 3, the exons 2/3a probe was designed as a control to define all the variants. It detected several diffuse and heavy bands ranging from 2 to 15 kb. A similar

band pattern was also seen in the mouse and rat Northern blots with their exons 2/3a probes. The exon 5a probe hybridized a strong band around 12 kb, which had a similar size and an intensity when compared to the higher band detected by the exon 4 probe that defines the original human MOR-1. This similarity implied that there was a relatively high abundance for the variants
5 associated with exon 5a. The exon 5a probe also hybridized several light diffuse bands at approximately 15, 3.5 to 5 and 2 to 3 kb, respectively, suggesting that exon 5a may be associated with multiple variants. However, the exons 5b, 5c, 5d, 5e and Y probes as well as exon 3b probe all detected a well-defined band at about 15 kb, suggesting that they may share a similar RNA structure, particularly in the 3'UTR, even if the protein sequences are different. The exon Y
10 probe also hybridized two distinct bands at approximately 12 and 3.5 kb. Although the smaller one may be a degradation product, it also is possible that exon Y may be associated with more than one variant.

Table 1 depicts the identity and homology among the human mu opioid receptor variants.

Table 2 presents the saturation studies with [³H]DAMGO. [³H]DAMGO binding was
15 performed in membranes isolated from stable transfectants containing the indicated cDNA clones. The binding parameters were established by nonlinear regression analysis. Results are the mean ± S.E.M of at least three independent determinations.

Table 3 presents the competition of [³H]DAMGO binding among the human MOR-1 variants. Competition studies against [³H]DAMGO (~1nM) were performed with indicated
20 ligands using at least three concentrations of drugs and the Ki value calculated as previously described. Results are the means ± S.E.M. of three independent determinations. The ligands that showed significant differences among the variants using ANOVA were DAMGO (p<0.0262), Morphine (p<0.0359), M6G (p<0.0003), DSLET (p<0.0027), endomorphin 1 (p<0.0068), endomorphin 2 (p<0.0084), β-endorphin (p<0.0005). For DAMGO, Tukey determined
25 differences between hMOR-1(exons 1-3) and hMOR-1B2, hMOR-1B1 and hMOR-1B2, hMOR-1B3 and hMOR-1B2 (p<0.05). For morphine, Tukey determined differences between hMOR-1(exons 1-3) and hMOR-1B2, hMOR-1B1 and hMOR-1B2, hMOR-1B2 and hMOR-1B3 (p<0.05). For M6G, Tukey determined differences between hMOR-1 and hMOR-1B2, hMOR-1(exons 1-3) and hMOR-1B2, hMOR-1A and hMOR-1B2, hMOR-1B1 and hMOR-1B2, hMOR-30 1B2 and hMOR-1B3(p<0.01). For DSLET, Tukey determined differences between hMOR-1 and hMOR-1B2(p<0.05), hMOR-1(exons 1-3) and hMOR-1B2 (p<0.01), hMOR-1A and hMOR-1B2

($p<0.05$), hMOR-1B1 and hMOR-1B2, hMOR-1B2 and hMOR-1B3, hMOR-1B2 and hMOR-1B5, hMOR-1B2 and hMOR-1Y ($p<0.01$). For endomorphin 1, Tukey determined differences between hMOR-1 and hMOR-1B2, hMOR-1(exons 1-3) and hMOR-1B2, hMOR-1B1 and hMOR-1B2 ($p<0.05$). For endomorphin 2, Tukey determined differences between hMOR-1 and hMOR-1(exons 1-3), hMOR-1 and hMOR-1A, hMOR-1 and hMOR-1B1, hMOR-1 and hMOR-1B3 ($p<0.05$). For β -endorphin, Tukey determined differences between hMOR-1 and hMOR-1B2, hMOR-1(exons 1-3) and hMOR-1B2, hMOR-1A and hMOR-1B2, hMOR-1B1 and hMOR-1B2, hMOR-1B2 and hMOR-1B3 ($p<0.01$).

Table 4 depicts saturation studies with [3 H]DAMGO. [3 H]DAMGO binding was performed in membranes isolated from stable transfectants containing the indicated rat cDNA clones. The binding parameters were established by nonlinear regression analysis. Results are the mean \pm S.E. of at least three independent determinations.

Table 5 present the relative efficacy of opioid ligands for hMOR-1 and hMOR-1 variants in adenylyl cyclase assay. The highest level of inhibition for any of the drugs (Table 4) for a specific variant was arbitrarily defined as 100%. Efficacy for all the other compounds for the indicated variant was defined as the percentage of the maximal inhibition for that variant.

Table 6 depicts the inhibition of forskolin-stimulated cAMP accumulation by opioids in hMOR-1 variants. The IC₅₀ and maximal inhibition were calculated by nonlinear regression analysis (Prism 3.0). Results are the means \pm S.E.M. of at least three independent determinations. Significant differences of maximal inhibition analyzed by ANOVA were DAMGO ($p<0.0001$), and morphine ($p<0.0001$). For maximal inhibition by DAMGO, post hoc analysis using Tukey revealed significant differences between hMOR-1 and hMOR-1B1 ($p<0.05$), hMOR-1A and hMOR-1B1 ($p<0.01$), hMOR-1B1 and hMOR-1B2 ($p<0.001$), hMOR-1B1 and hMOR-1B5 ($p<0.01$), hMOR-1B1 and hMOR-1B6 ($p<0.001$), hMOR-1B2 and hMOR-1B4 ($p<0.01$), hMOR-1B3 and hMOR-1B6 ($p<0.05$), hMOR-1B4 and hMOR-1B6 ($p<0.01$). For maximal inhibition by morphine, Tukey determined significant differences between hMOR-1 and hMOR-1B3, hMOR-1(exons 1-3) and hMOR-1B3, hMOR-1A and hMOR-1B3 ($p<0.001$), hMOR-1B1 and hMOR-1B6 ($p<0.01$), hMOR-1B2 and hMOR-1B4 ($p<0.05$), hMOR-1B3 and hMOR-1B4, hMOR-1B4 and hMOR-1B6 ($p<0.01$), hMOR-1B3 and hMOR-1B5, hMOR-1B3 and hMOR-1B6 ($p<0.001$). Significant differences of IC₅₀ by ANOVA were DAMGO ($p<0.0008$), morphine ($p<0.0002$), β -endorphin ($p<0.0001$). For IC₅₀ by DAMGO, Tukey determined

significant differences between hMOR-1 and hMOR-1B1, hMOR-1B1 and hMOR-1(exons 1-3) (p<0.01), hMOR-1 and hMOR-1B3, hMOR-1(exons 1-3) and hMOR-1B3, hMOR-1A and hMOR-1B1, hMOR-1B1 and hMOR-1B6 (p<0.05). For IC₅₀ by morphine, Tukey determined significant differences between hMOR-1 and hMOR-1B2, hMOR-1(exons 1-3) and hMOR-1B2 (p<0.001), hMOR-1A and hMOR-1B2, hMOR-1B2 and hMOR-1B3, hMOR-1B2 and hMOR-1B4, hMOR-1B2 and hMOR-1B5, hMOR-1B2 and hMOR-1B6 (p<0.01). For IC₅₀ by β -endorphin, Tukey determined significant differences between hMOR-1 and hMOR-1B5, hMOR-1A and hMOR-1B5, hMOR-1B1 and hMOR-1B5, hMOR-1B5 and hMOR-1B6 (p<0.001), hMOR-1B3 and hMOR-1B5, hMOR-1B4 and hMOR-1B5 (p<0.01)

Table 1

Identity (Homology)	hMOR-1 (400)	hMOR-1A (392)	hMOR-1B1 (406)	hMOR-1B2 (397)	hMOR-1B3 (403)	hMOR-1B4 (389)	hMOR-1B5 (410)	hMOR-1O (418)	hMOR-1X (446)	hMOR-1Y (402)
hMOR-1 (400)										
hMOR-1A (392)	97.3 (99.3)									
hMOR-1B1 (406)	96.1 (97.5)	95.8 (99.3)								
hMOR-1B2 (397)	97.3 (98.0)	97.7 (99.0)	96.1 (98.3)							
hMOR-1B3 (403)	96.5 (97.3)	97.7 (99.0)	95.8 (96.6)	96.5 (98.0)						
hMOR-1B4 (389)	96.8 (99.5)	98.7 (99.5)	95.3 (99.5)	97.5 (99.5)	96.0 (99.5)					
hMOR-1B5 (410)	95.6 (98.0)	94.5 (99.3)	94.4 (97.3)	95.1 (98.3)	94.9 (96.6)	94.4 (99.5)				
hMOR-1O (418)	92.8 (97.1)	92.8 (99.0)	92.8 (95.7)	92.8 (97.8)	93.5 (97.1)	92.6 (99.5)	93.3 (95.2)			
hMOR-1X (446)	87.0 (97.3)	87.0 (99.1)	87.7 (96.6)	87.4 (98.4)	87.2 (96.9)	86.8 (99.6)	87.7 (95.7)	87.4 (93.7)		
hMOR-1Y (402)	96.5 (97.0)	96.8 (99.3)	95.8 (96.8)	96.5 (97.8)	96.3 (96.5)	94.6 (96.6)	93.1 (96.9)	87.2 (97.1)		

Table 2

Clone	K _D (nM)	B _{max} (pmol/mg protein)
hMOR-1	1.6 ± 0.6	1.01 ± 0.20
hMOR-1(exons 1-3)	1.2 ± 0.3	0.66 ± 0.09
hMOR-1A	1.7 ± 0.6	1.04 ± 0.13
hMOR-1B1	3.1 ± 0.8	0.49 ± 0.08
hMOR-1B2	4.4 ± 0.4	0.37 ± 0.04
hMOR-1B3	1.6 ± 0.5	0.37 ± 0.02
hMOR-1B4	2.6 ± 0.2	0.56 ± 0.10
hMOR-1B5	1.4 ± 0.1	0.44 ± 0.08
hMOR-1Y	2.3 ± 0.6	0.69 ± 0.15

Table 3

Ligand	K_i value (nM)								
	hMOR-1wt	hMOR-1 w/o exon 4	hMOR-1A	hMOR-1B1	hMOR-1B2	hMOR-1B3	hMOR-1B4	hMOR-1B5	hMOR-1B6
DAMGO	2.0 ± 0.8	1.5 ± 0.4	2.4 ± 0.6	1.2 ± 0.7	5.8 ± 2.4	1.8 ± 0.9	2.3 ± 1.1	2.1 ± 0.7	2.5 ± 1.4
Morphine	4.2 ± 1.4	2.9 ± 0.9	4.4 ± 1.7	2.4 ± 2	11.2 ± 6.1	3.2 ± 1.1	5.5 ± 3	3.9 ± 1.6	4.3 ± 3
M6G	13.9 ± 3.2	11 ± 4.6	13.2 ± 6.6	5 ± 0.4	42.2 ± 13.7	15.7 ± 2.1	22.8 ± 12.9	12.2 ± 4.5	8.3 ± 3.9
DADLE	3.9 ± 1.3	4.5 ± 1.5	4.9 ± 1.1	3.6 ± 2.6	10 ± 5.9	4.6 ± 0.4	5.1 ± 2.1	6.8 ± 2.8	6.5 ± 3
DSLET	19.1 ± 5.8	14 ± 2	19.7 ± 7.7	13.9 ± 4.9	34.4 ± 6.4	16.4 ± 2.8	22.3 ± 2	16 ± 6.6	15.4 ± 3.5
Naloxone	2.9 ± 0.5	1.8 ± 0.4	4.5 ± 3	1.5 ± 0.5	5.8 ± 3.5	2.2 ± 0.7	4.6 ± 1.9	2.7 ± 0.3	2.9 ± 1.3
Endomorphin 1	4.2 ± 2.5	3.9 ± 3	7.7 ± 3.3	3.8 ± 1.3	11.5 ± 0.1	4.9 ± 2.5	9.9 ± 4	4.6 ± 0.5	5.1 ± 2
Endomorphin 2	34.1 ± 25.4	4.6 ± 1.3	5.6 ± 3	5.4 ± 1.1	19.9 ± 2.2	6.3 ± 2.5	22.5 ± 3.4	9.6 ± 5.2	9.4 ± 5.1
β -Endorphin	3.5 ± 0.1	4.3 ± 2.2	6.6 ± 2.9	7.8 ± 2.7	24.7 ± 8.8	8.2 ± 3.8	16 ± 0.7	10 ± 5.8	8.4 ± 3
Dynorphin A	8.6 ± 0.3	47.4 ± 9.6	8.4 ± 1.9	19.3 ± 11.4	49 ± 38.5	13.8 ± 4	70.5 ± 51.1	52.7 ± 39.3	24.7 ± 22.5
DPDPE	> 500	> 500	> 500	> 500	> 500	> 500	> 500	> 500	> 500
US0,488H	> 500	> 500	> 500	> 500	> 500	> 500	> 500	> 500	> 500

001175572

Table 4

Clone	K _D (nM)	B _{max} (pmol/mg protein)
rMOR-1	2.8 ± 0.79	2.94 ± 0.45
rMOR-1 no E 4	4.5 ± 1.1	0.39 ± 0.06
rMOR-1A	2.5 ± 0.2	0.81 ± 0.06
rMOR-1C1	4.8 ± 0.6	1.82 ± 0.29
rMOR-1D	4.7 ± 1.2	0.51 ± 0.05

Table 5

(% Maximal Inhibition)	DAMGO	Morphine	B-Endorphin
hMOR-1	84	89	88
hMOR-1 (exons 1-3)	81	83	81
hMOR-1A	90	92	81
hMOR-1B1	63	76	72
hMOR-1B2	99	98	72
hMOR-1B3	80	51	81
hMOR-1B4	71	76	77
hMOR-1B5	91	86	77
hMOR-1Y	100	100	100

Table 6

Ligand	DAMGO				Morphine				β-Endorphin	
	IC ₅₀	IC ₅₀ /K _i	Max Inhib (%)	IC ₅₀ /K _i	Max Inhib (%)	IC ₅₀	IC ₅₀ /K _i	Max Inhib (%)		
hMOR-1	2 ± 0	1.0	76 ± 4	4 ± 1	0.9	74 ± 6	13 ± 3	0.3	79 ± 2	
hMOR-1 (exons 1-3)	3 ± 1	2.0	74 ± 3	5 ± 1	1.7	69 ± 6	16 ± 4	3.7	73 ± 4	
hMOR-1A	5 ± 2	2.1	82 ± 1	9 ± 3	2.0	76 ± 1	22 ± 3	3.3	73 ± 2	
hMOR-1B1	46 ± 17	38.3	57 ± 2	47 ± 19	19.6	63 ± 2	34 ± 4	4.4	65 ± 4	
hMOR-1B2	29 ± 7	5.0	90 ± 3	72 ± 16	6.4	81 ± 1	108 ± 34	4.4	65 ± 5	
hMOR-1B3	38 ± 7	21.1	73 ± 8	11 ± 4	3.4	42 ± 1	48 ± 12	5.9	73 ± 9	

Ligand	DAMGO				Morphine				β-Endorphin			
	IC ₅₀	IC ₅₀ /K _i	Max Inhib (%)	IC ₅₀ /K _i	Max Inhib (%)	IC ₅₀	IC ₅₀ /K _i	Max Inhib (%)	IC ₅₀	IC ₅₀ /K _i	Max Inhib (%)	
hMOR-1B4	20 ± 3	8.7	65 ± 3	8 ± 2	1.5	63 ± 2	60 ± 16	3.8	69	69 ± 5		
hMOR-1B5	34 ± 5	16.1	83 ± 1	19 ± 2	4.9	71 ± 1	217 ± 50	21.7	69	69 ± 8		
hMOR-1Y	8 ± 2	3.2	91 ± 2	9 ± 2	2.1	83 ± 3	44 ± 16	5.2	90	90 ± 2		

Characterization of expressed variants. In order to study pharmacological functions of the variants, CHO cell lines stably transfected with individual variant cDNAs whose expression was under control of a human cytomegalovirus (CMV) early promoter, a common promoter used in mammalian expression system, were obtained. As a control, a stable cell line expressing a receptor that only contained exons 1-3 without a fourth exon was included. In saturation studies, [³H] DAMGO revealed high affinity for all the variants with little difference among their K_D values (Table 2). Competition studies with a variety of opioids further demonstrated that all the variants encoded a mu opioid receptor (Table 3). The mu ligands such as DAMGO, morphine and M6G all competed binding with high affinities, while the delta-selective ligand DPDPE and the kappa₁-selective opioid, U50,488H were inactive. The control receptor (hMOR-1 (exons 1-3)) showed a high affinity toward [³H] DAMGO in saturation studies and the similar mu-selective binding profile in competition studies, suggesting that the ligand binding was not very dependent on the carboxyl termini encoded by the different fourth exons. It was not surprising because they all had the same N-terminal seven transmembrane structure that comprises binding motifs for mu ligands. However, the variants did display subtle but significant binding pocket differences. For example, endomorphin 2 competed binding to the hMOR-1 over 5- to 7-fold less potently than against hMOR-1A, hMOR-1B1, hMOR-1B3 and hMOR-1 (exons 1-3) ($p < 0.05$), respectively. β -endorphin showed lower affinities toward hMOR-1B2 and hMOR-1B4 as compared to other variants. Interestingly, compared to the other variants, hMOR-1B2 had relative lower affinities for all the mu agonists including DAMGO, morphine, M6G and endomorphin 1, but maintained a high affinity for naloxone. The carboxyl terminal sequence of hMOR-1B2 which encoded by exon 5b was quite unique with four basic residues in a total of nine amino acids. It also contained a potential cAMP- and cGMP-dependent protein kinase phosphorylation site.

Since the structures of all the variants differ from each other only at their carboxyl termini which are all located at intracellular side, there may be differences in their coupling to G protein transduction pathway. Mu opioid receptors are mainly coupled to Gi/Go and associated with inhibition of adenylyl cyclase to reduce the intracellular level of cAMP, an important second messenger system within cells. The effect of several opioids on forskolin-stimulated cAMP accumulation in intact cells expressing the variants was investigated.

The results showed striking differences in the effect of opioids on inhibiting cAMP production (Tables 3 and 4). This could be seen in both their potency determined by the IC₅₀ values, and efficacy indicated by the percentage of maximal inhibition. DAMGO and morphine, which displayed the limited differences among the variants in binding assays, revealed their IC₅₀ values that varied from 3- to 23-fold. β-endorphin IC₅₀ values also differed from 3- to 16-fold. The ratio of the IC₅₀/Ki values that takes account for binding affinities of the opioids is another measurement for comparing their potencies. Again, there were marked differences of potencies among the variants. For example, the DAMGO IC₅₀/Ki value for hMOR-1B1 was over 38-fold than that for hMOR-1. Although β-endorphin IC₅₀ value varied over 16-fold between hMOR-1 and hMOR-1B5, their IC₅₀/Ki value differed by over 72-fold. Therefore, different carboxyl termini can indeed affect the potency of opioids to inhibit forskolin-stimulated cAMP accumulation in intact cells independent of their binding affinities.

Marked differences in the maximal inhibition (%), an indication of the opioid efficacy, were also observed among the variants (Tables 3 and 4). The ranges of the maximal inhibitions for DAMGO, morphine and β-endorphin were 63 – 100%, 51 – 100% and 72 – 100%, respectively (Table 5). Interestingly, hMOR-1Y had the highest efficacy for all the opioids, whereas the lowest efficacies for the opioids varied among the variants. hMOR-1B1 showed the lowest efficacy (63%) for DAMGO, while hMOR-1B1 and hMOR-1B2 had the lowest efficacy (72%) for morphine. hMOR-1B3 displayed only 51% of efficacy. There was little correlation between their potencies and efficacies. For example, morphine had the same efficacy for hMOR-1B1 and hMOR-1B4, but there was a 13-fold difference in their IC₅₀/Ki values. On the other hand, in binding assays hMOR-1B2 had relatively low affinities toward DAMGO and morphine, but both opioids showed higher efficacies for hMOR-1B2, when compared to those for other variants. It also was interesting to observe that the relative efficacy of the different opioids for an individual variant varied (Table 5). For example, DAMGO and morphine were more efficacious than β-endorphin against hMOR-1B2, while β-endorphin and DAMGO were more effective than morphine against hMOR-1B3.

There was no association between binding affinity and potency or efficacy among the human variants for a number of drugs, which was similar to results obtained from the mouse MOR-1 variants by using the [³⁵S]GTP(S binding assay (see, e.g., Bolan et al. (2000) Soc.Neurosci. 26, 112), which is another method for assessing receptor signalling. Although

different human variants often bind the same ligand equally well, the functional consequences, as indicated by their abilities to inhibit forskolin-stimulated cAMP accumulation, were distinct from each other. One implication of these studies is to potentially develop selective drugs based upon their efficacy and/or potency.

5 Together with the hMOR-1A, hMOR-1O and hMOR-1X variants previously isolated, there now are a total of nine human splice variants. The extensive alternative splicing first demonstrated in mouse now applies to human. All the nine variants were carboxyl terminal variants resulted from alternative splicing of the fourth exon. The different protein structures at their carboxyl tips had the limited effect on the binding selectivity of the variants, but all
10 dramatically altered signaling thought through their interaction with G protein system. This dissociation of binding affinity and efficacy or potency for the variants, together with their potential region-specific expression, may provide insight to understand different pain thresholds and different opioid responses in human, and to design novel selective or individualized drugs that modulate pain based upon their efficacy/potency.

15 EXAMPLE 2: Identification and characterization of five new splice variants (rMOR-1C1, rMOR-1C2, rMOR-1D, rMOR-1B2, and rMOR-1E) of the rat *Oprm* gene

Five splice variants (rMOR-1C1, rMOR-1C2, rMOR-1D, rMOR-1B2, and rMOR-1E) of the rat *Oprm* gene from rat brain have been identified. The main strategy used for isolating the human and rat variants was to search the homologous variants in rat using the mouse variant
20 sequences either by comparing with public rat genome databases (NCBI and Ensembl) or by directly using the mouse sequences to perform RT-PCT. All the rat variants contained the same exons 1, 2 and 3 as their original MOR-1, but had a different fourth exon. Therefore, all of the variants are carboxyl terminal variants. Although the variants were obtained by using the mouse sequences and shared some degree of homology at nucleotide level with the mouse sequences,
25 all the predicted amino acid sequences from the alternative fourth exons were totally different from any of the mouse sequences identified so far. Northern blot analysis with appropriate exon probes revealed distinct band patterns with different sizes and intensities.

The variants were expressed in CHO cells and characterized them by opioid binding, [³⁵S]GTP-γ-S binding and adenylyl cyclase assays. The binding results showed that all the
30 variants had higher affinity to mu-specific opioids and lower affinity to kappa or delta drugs, a similar profile revealed by the original MOR-1. This could be seen in both their potency

determined by the IC₅₀ values, and efficacy indicated by the percentage of maximal inhibition. The results from [³⁵S]GTP-γ-S binding assay of the rat variants revealed marked differences in the ability of the opioids to stimulate [³⁵S]GTP-γ-S binding in terms of both their potency determined by the EC₅₀ and efficacy indicated as maximal stimulation. The different protein structures at carboxyl tips among the variants had the limited effect on their binding selectivity, but they do affect forskolin-stimulated adenylyl cyclase activity, presumably through their interaction with G proteins, as well as [³⁵S]GTP-γ-S binding. This dissociation of binding affinity and efficacy or potency for the variants, together with their potential region-specific expression, may provide an important insight to understand different pain thresholds and 10 different opioid responses in human and rat, and to design novel selective or individualized drugs that modulate pain based upon their efficacy/potency.

Table 7 presents the selectivity of rMOR-1 splice variants in [³H]DAMGO binding assay. Competition studies were performed in [³H]DAMGO (~1 nM) binding assay using at least three concentrations of the indicated ligand with membranes from the same stable transfectant. 15 ANOVA was performed, followed by Tukey's post hoc analysis. Results are the mean ± S.E. of at least three independent determinations.

Table 8 depicts the effects of opioid on [³⁵S]GTPγS binding in the rat MOR-1 splice variants. Basal [³⁵S]GTPγS binding was assessed in membranes from cells stably transfected with the individual variants. The ability multiple concentrations of of the indicated opioid to 20 stimulate [³⁵S]GTPγS binding was determined. The maximal stimulation was defined as the percent increase over basal binding, and the dose of drug needed to elicit 50% of the maximal response, the EC50. Results are the means ± S.E.M. of at least three independent determinations.

Table 7

Ligand	Ki Value (nM)				ANOVA	Tukey
	rMOR-1	rMOR-1 (no E4)	rMOR-1A	rMOR-1C1		
Morphine	5.6 ± 0.8	6.5 ± 0.6	8.0 ± 0.4	7.4 ± 0.3	7.4 ± 0.5	N.S.
M6G	16.9 ± 2.2	20.5 ± 2.8	25.7 ± 2.1	24.8 ± 2.4	21.0 ± 1.8	N.S.
DAMGO	3.3 ± 0.6	2.4 ± 0.4	6.0 ± 0.9	4.5 ± 0.9	4.7 ± 1.2	N.S.
DADLE	4.3 ± 0.5	6.8 ± 1.3	8.1 ± 0.4	8.6 ± 1.0	5.4 ± 0.3	N.S.
DSLET	30.9 ± 1.9	24.2 ± 1.9	44.5 ± 5.1	45.0 ± 8.7	27.3 ± 7.3	N.S.
Endomorphin 1	4.1 ± 0.7	4.4 ± 0.1	6.5 ± 0.3	3.9 ± 0.1	3.9 ± 0.4	< 0.05
					1 vs 1A	< 0.05
					1A vs 1C1	< 0.05
					1A vs 1C2	< 0.05
Endomorphin 2	8.0 ± 2.0	9.1 ± 0.7	11.5 ± 0.6	10.1 ± 0.6	7.5 ± 0.4	N.S.
β-Eンドルフィン	3.7 ± 0.4	10.0 ± 0.8	10.5 ± 0.6	8.8 ± 0.5	8.5 ± 0.6	< 0.0005
					1 vs 1E4	< 0.001
					1 vs 1A	< 0.001
					1 vs 1C1	< 0.01
					1 vs 1C2	< 0.01
Dynorphin A	12.4 ± 3.0	14.0 ± 1.4	22.8 ± 1.6	12.5 ± 2.3	10.8 ± 1.7	< 0.05
					1A vs 1C2	< 0.05

Ligand	Ki Value (nM)				Tukey		p
	rMOR-1	rMOR-1 (no E4)	rMOR-1A	rMOR-1C1	rMOR-1D	ANOVA	
Naloxone	3.2 ± 0.4	4.1 ± 0.4	5.0 ± 0.9	5.4 ± 0.9	2.6 ± 0.8	N.S.	
U50,488H	> 500	> 500	> 500	> 500	> 500		
DPDPE	> 500	> 500	> 500	> 500	> 500		

Table 8

Ligand	rMOR-1			rMOR-1 (no Exon 4)			rMOR-1A			rMOR-1C1			rMOR-1D		
	EC50 (nM)	EC50 /Ki	Max Stim (%)	EC50 (nM)	EC50 /Ki	Max Stim (%)	EC50 (nM)	EC50 /Ki	Max Stim (%)	EC50 (nM)	EC50 /Ki	Max Stim (%)	EC50 (nM)	EC50 /Ki	Max Stim (%)
DAMGO	12 ± 3	3.6	233 ± 44	86 ± 16	35.8	196 ± 37	13 ± 5	2.2	176 ± 24	74 ± 22	16.4	233 ± 45	125 ± 26	26.6	113 ± 22
DADLE	24 ± 5	5.6	298 ± 26	401 ± 38	59.0	225 ± 24	63 ± 23	7.8	175 ± 8	128 ± 15	14.8	379 ± 62	300 ± 29	55.6	204 ± 23
DSLET	76 ± 17	2.5	251 ± 5	690 ± 179	28.5	226 ± 15	127 ± 45	2.9	206 ± 23	253 ± 75	5.6	312 ± 19	540 ± 129	19.7	187 ± 19
Endomorphine	14 ± 4	3.4	320 ± 23	114 ± 11	25.9	189 ± 16	15 ± 3	2.3	205 ± 34	54 ± 8	13.8	377 ± 40	100 ± 26	25.6	145 ± 29
β-Endorphin	4 ± 2	1.1	246 ± 52	90 ± 20	9.0	240 ± 16	13 ± 5	1.2	177 ± 28	48 ± 4	5.5	361 ± 41	91 ± 14	10.7	165 ± 42

All references cited herein, are hereby incorporated herein. Although the foregoing invention has been described in some detail, by way of illustration and example for the purposes of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications can be made. Therefore, the description and examples should not be construed 5 as limiting the scope of the invention, which is delineated by the appended paragraphs and/or claims.

The invention is further described by the following numbered paragraphs:

1. An isolated hMOR-1B1 splice variant polypeptide that consists essentially of the 10 amino acid residues having the sequence of SEQ ID NO:50.
2. An isolated hMOR-1B2 splice variant polypeptide that consists essentially of the amino acid residues having the sequence of SEQ ID NO:52.
3. An isolated hMOR-1B3 splice variant polypeptide that consists essentially of the amino acid residues having the sequence of SEQ ID NO:54.
4. An isolated hMOR-1B4 splice variant polypeptide that consists essentially of the 15 amino acid residues having the sequence of SEQ ID NO:56.
5. An isolated hMOR-1B5 splice variant polypeptide that consists essentially of the amino acid residues having the sequence of SEQ ID NO:58.
6. An isolated hMOR-1Y splice variant polypeptide that consists essentially of the 20 amino acid residues having the sequence of SEQ ID NO:60.
7. The polypeptide as in one of the preceding paragraphs in which the polypeptide comprises a heterodimeric or homodimeric composition.
8. An isolated polynucleotide, or an antisense strand that is fully complementary thereto, wherein the nucleotide fragment consists essentially of hMOR-1B1, having the sequence of SEQ 25 ID NO 51.
9. An isolated polynucleotide, or an antisense strand that is fully complementary thereto, wherein the nucleotide fragment consists essentially of hMOR-1B2, having the sequence of SEQ ID NO 53.
10. An isolated polynucleotide, or an antisense strand that is fully complementary thereto, 30 wherein the nucleotide fragment consists essentially of hMOR-1B3, having the sequence of SEQ ID NO 55.

11. An isolated polynucleotide, or an antisense strand that is fully complementary thereto, wherein the nucleotide fragment consists essentially of hMOR-1B4, having the sequence of SEQ ID NO 57.

12. An isolated polynucleotide, or an antisense strand that is fully complementary thereto, 5 wherein the nucleotide fragment consists essentially of hMOR-1B5, having the sequence of SEQ ID NO 59.

13. An isolated polynucleotide, or an antisense strand that is fully complementary thereto, wherein the nucleotide fragment consists essentially of hMOR-1Y, having the sequence of SEQ ID NO 61.

10 14. A method of screening compositions for opioid activity comprising the steps of: a) obtaining a control cell that does not express an MOR-1 splice variant polypeptide; b) obtaining a test cell that is the same as the control cell except that it expresses an MOR-1 splice variant polypeptide as in any one of paragraphs 1-6; c) contacting the control cell and test cell with an amount of an opioid sufficient to exert a physiologic effect; d) separately measuring the 15 physiologic effect of the composition on the control cell and test cell; and e) comparing the physiologic effect of the composition to the physiologic effect of the opioid, where determination of a physiologic effect of the composition is expressed relative to that of the opioid.

20 15. The method according to paragraph 14, where the composition is selected from the group consisting of synthetic combinatorial libraries of small molecule ligands, eukaryotic whole cell lysates or extracts, or media conditioned by cultured eukaryotic cells.

25 16. The method according to paragraph 14, where the opioid is selected from the group consisting of morphine, methadone, etorphine, levorphanol, fentanyl, sufentanil, [D-Ala₂,MePhe₄,Gly(ol)₅]enkephalin, pentazocine, ethylketocyclazocine, bremazocine, spiradoline, [D-Ser₂,Leu₅]enkephalin-Thr₆, Met-enkephalin, Leu-enkephalin, (3-endorphin, dynorphin A, dynorphin B, or a-neoendorphin.

17. The method according to paragraph 14, where the physiological effect is measured by changes in the levels of neuroendocrine hormones.

30 18. The method according to paragraph 17, where the hormone is selected from the group consisting of prolactin, growth hormone, gonadotropin-releasing hormone, adrenocorticotropin, corticotropin-releasing factor, luteinizing hormone, follicle stimulating hormone, testosterone or cortisol.

19. A method of screening compositions for opioid binding activity comprising the steps of: a) obtaining a control polypeptide that is not an MOR-1 splice variant polypeptide; b) obtaining a test polypeptide that is an MOR-1 splice variant polypeptide as in any one of paragraphs 1-6; c) contacting a composition with the control polypeptide and the test polypeptide; d) contacting the test polypeptide with an amount of an opioid sufficient to measurably bind the test polypeptide; e) measuring the binding of the composition and the opioid; and f) comparing test polypeptide binding of the composition to that of the opioid, where determination of binding of the composition is expressed relative to that of the opioid.

5 20. The method according to paragraph 21 where the composition is selected from the group consisting of synthetic combinatorial libraries of small molecule ligands, eukaryotic whole cell lysates or extracts, or media conditioned by cultured eukaryotic cells.

10 21. A method for regulating morphine analgesia in a subject comprising altering the amount of MOR-1 splice variant activity by: a) administering antigen binding fragments to a subject in an amount and a duration sufficient to regulate morphine analgesia; or b) 15 administering agonists to a subject in an amount and a duration sufficient to regulate morphine analgesia; or c) administering antagonists to a subject in an amount and a duration sufficient to regulate morphine analgesia; or d) administering small molecule ligands to a subject in an amount and a duration sufficient to regulate morphine analgesia; or d) administering an antisense nucleic acid corresponding to a nucleic acid comprising a polypeptide encoding a polypeptide 20 selected from the group consisting of a MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR-1 opioid-binding activity, to a subject in an amount and a duration sufficient to regulate morphine analgesia; and wherein the antigen binding fragment, agonist, antagonist small molecule ligand or antisense nucleic acid is directed to an MOR-1 splice variant as in any one of paragraphs 1-6.

25

WHAT IS CLAIMED IS:

(THIS PAGE INTENTIONALLY LEFT BLANK)

ABSTRACT OF THE DISCLOSURE

The present invention encompasses novel splice variant forms of the mu- opioid receptor-1 (MOR-1) and the polynucleotide sequences encoding the MOR-1 splice variants. The invention further encompasses methods of screening for compositions regulating the MOR-1 splice variant activities and the development of therapeutic modalities directed to regulating activity. Regulation of the MOR-1 splice variant activities may impact the physiologic process of analgesia.

5

Genomic Structure of the human mu opioid receptor gene




FIG. 1A (SHEET 1 OF 26)

\00168102

hMOR-1A

Exon 3a ↓ **Exon 3b**

---ACTAATCATCAGGTACGGCAGTCTAGAATTAGGTATATCTACTGGGATGACATAAAAATTATAAGGCCTT

T N H Q V R S L * (SEQ ID NO: 27)

TGTGCTAACTAGGAGTTAACCTATTAGGGATGAGAATTGGAGGGAAAGCAAGGG (SEQ ID NO: 28)

hMOR-1B1

Exon 3a ↓ **Exon 5a**

---ACTAATCATCAGAAAATAGATTTCAGAAATCTGACTCAACTTGAGCATACCAAGGGCTAAATA

T N H Q K I D L F Q K S **S[#]** L L N C E H T K G * (SEQ ID NO: 29)
ATTACAATATTTCGGTGAAGAATATAAGATTGGAAGC (SEQ ID NO: 30)

hMOR-1B2

Exon 3a ↓ **Exon 5b**

---ACTAATCATCAGAGAGAAAGACAGAAATCTGACTGGTAAGAAATTGTTACCCCTTTGCCAGCATGCCA

T N H Q R E R R Q K **S[#]** D W * (SEQ ID NO: 31)

GGCTTCTGGGTTCCCTTCCCTGAGCGGCCCTAGTAGTATCCGGCCTACGGGCC--- (SEQ ID NO: 32)

hMOR-1B3

Exon 3a ↓ **Exon 5c**

---ACTAATCATCAGGGACCTCCAGCCAAGTTGCTGACCAAACITGCCGGGTCTTGTAAAGGGGCTT

T N H Q G P P A K F V A D Q L A G S S * (SEQ ID NO: 33)
ACAGGTGTTCCAAGCCCCGTGTTTATCCCTGAAGTATCCCTCAACACAGAAAAACGACCTCATAACACAAAA--- (SEQ ID NO: 34)

hMOR-1B4

Exon 3a ↓ **Exon 5d**

---ACTAATCATCAGAGCTGACTATGACATGAACCTAAATTCCCTGTTCCC--- (SEQ ID NO: 35)

T N H Q S * (SEQ ID NO: 36)

FIG. 1B (SHEET 2 OF 26)




FIG. 1B (SHEET 3 OF 26)




FIG. 2 (SHEET 4 OF 26)

hMOR-1B1 (1354 bp)

CGGAAAGGGCTGAGGGCTTGGAACCCAAAAGTCTCGGTACCTGGCTACAGGGTCCCCCCCC
GGCGTCAGTACCATGGACAGCAGGCCAGCAACTGGTCAACTGGTCCCACTAGATGGCAACCTGGTCCCGAAC
CTCCCCAGCAGCCCCGGTTCTGGTCAACTGGTCCCACTAGATGGCAACCTGGTCCCGAACCCATGGGGTCCCGAAC
CGCACCGACCTGGGGAGAGACAGCCCTGTGCCAGGGCAGTCCCATGATCACGGCCATCACGATCATG
GCCCTCTACTCCATCGTGTGGCTCTCGGAAACTTCCCTGGTCAATGTATGTGATTGTCAGATAACCAAAGAT
GAAGACTGCCACCAACATCTACATTTCAACCTTGGCAGATGCCCTAGGCCACCGTAGCCCTTCAAGCT
GTGAATTACCTAATGGGAACATGGCCATTGGAAAGATAAGTGAATTACTATAACATGT
TCACCAGCATATTCAACCCCTCTGCACCATTGAGTGTGATCGATA
CGTACTCCCCGAAATGCCAAATATTCAATGTCTGCAACTGGATCCCTCTCGCATGGTCTGGTACACTGGTACATTCT
GGCTACAACAAATAACAGGCAAGGGTTCCATAGATTGTACACTAACATTCTCTCATCCAAACCTGGTACTGGGAAAACCTG
CTGAAGATCTGTGTTCATCTTCCCTCATTATGCCACTGCTCATCGTCTGGACTATGGACTGATCTGGCG
CCTCAAGAGACTGTCCGGCATGCTCTGGCTCCAAAGAAAAGGACAGGAATCTTCGAAGGATCACCAAGGATGGCTGGT
GGTGGTGGCTGTGTTCATCGTCTGGGACTCCATTACGTACATTACAGCTGGTACACAAACAGCTGCCCAACCCAGTCTTATGCA
CTACGTTCCAGACTGTTCTGCATTTGCACTTCTGGTACAGAGGTTCTGTATCCAAACCTCTCCAAACATTGAGGCAACAAAACCTCCA
TTCTGGATGAAACACTCAAACGATGCTTCAGAGGTTCTGTATCCAAACCTCTCCAAACATTGAGGCAACAAAACCTCCA
CTCGAATTCTGTCAGAACACTAGAGACCCCTCACGGCCAATACAGTGGATAGAACTAATCATCAGAAAATAGATT
TATTCAAAAGTCATCTTACTCAACTGTGAGCATACCAAGGGCTAATAATTACAATATTTCCTGAAAGAATATAA
GATTGGAAAGC (SEQ ID NO:50)

hMOR-1B1 (406 aa)

MDSSAAAPTNAASNCTDALA^YSSCSPAPSPGSSWVNLSHLDGNLSDPCGPNRTDLGGRDSSLCPPTGSPSMITAITIMALYSIVCVV
GLFGNFLVMYVIVRYTKMKTATNYIFNLALADALATSTL^PFQS^VNYL^MG^TWPFGTILCKIVISIDYYNNMFTSIFTLCTMSVDR
YIAVCHPVKA^LDFTPRNAKINVCNW^IS^AIGLPVVMEMATT^KYRQGSIDC^TLTFSHPTWY^WEN^LKKICVVFIAFIMPVLITY
CYGLMLRLKS^VRMLSGSK^EKDRNLRRITRMVLVVVA^VFIVCW^TPHIYVIKALVT^PETTFQTVSWHFCLALGYTN^SC^LNPV
LYAFLDENFKRCREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQKIDLFQKSSLNCEHTKG (SEQ ID NO:51)

FIG. 3A (SHEET 5 OF 26)

hMOR-1B2 (2218 bp)

CGGTGCTCCTGGCTACCTCGAACAGGGGCCGGCCGTCAAGTACCATGGACAGCAGCGCTGCCACCGAACG
CCAGCAATTGCACTGATGCCATTGGCTACTCAAGTGCCTGGCGTCCGACCTGGCCCTGGGTCAACTTGTCCCCA
CTTAGATGGCAACCTGTCGGTCCGACCCATGCCATTGGCTACTCAAGTGCCTGGGTCAACTTGTCCCCA
CGGCAGTCCCTCCATGATCACGGCCATCACGATTCACGATTCACGATTCACGATTCACGATTCACGATTCACG
TTCTGGTCATGTATGTGATTGATGGACTACCCAGTACCCCTGCCAGTGTGAATTACCTAATGGAAACATGGCCATT
AGATGGCTTAGGCCACCCAGTACCCCTGCCAGTGTGAATTACCTAATGGAAACATGGCCATTGGTAACACTGGC
TGCAAGAGATACTGATCTCCATAGATTACTATAACATGGTCAACCAGCATATTCAACCTCTGCACCATGAGTGTG
ACATTGGCAGTCTGCCACCCCTGTCAAGGCCCTAGATTCCGTAACCGCTTAAGAGTGTGGACTCCCGTACT
GATCCCTCTTCAGCCATTGGCTCCCTGTAATGGTCATGGCTACAAACAAATTACAGGCCAAGGGTCCATTAGATGT
TAACATTCTCTCATCCAAACCTGGTACTGGAAACCTGGCTGAAGAGATCTGTGTTTCATCTCGCCCTCATTATGCC
CTCATCATTACCGTGTGCTATGGACTGATGATCTTGCCCTCAAGAGTGTCCGGCATGCTCTGGCTCCAAGAAA
ACAGGAATCTCGAAGGGATCACCCAGGATGGTGGCTGGCTGGTTCAACATCCCAGAAACTACGTTCCAGACT
TTACGTCATCATTAAGCCTGGTTACAATCCCAGTCCTTATGCATTTCTGGATGAAACACTTCAAACGATGCT
GTTACACAAACAGCTGCCCTCAACCCAGTCCTTATGCATTTCTGGATGAAACACTTCAAACGATGCT
TATCCCAACCTCTCCAAACATTGAGCAACAAACTCCACTGGGAATTCTGAGTGGTAAGAAAATTGGTACCCCT
AATAACAGTGGATAGAAACTAATCATCAGAGAGAAAGACAGAAACTCTGACTGGTCAAGAAAATAGGAA
GCATGCCAGGGCTCTGGTTCCCTTCCCTGAGGGCCCTAGTGATCCGGCACCATGCCCTACGGGCCAAC
TGCAATCAAAGGAATTTTTTCAATTCTGGCCAGCAAAACACATGIGATAAAACATAGGCATTAGCT
AATAACAGTGGATAGAAACTAATCATCAGAGAGAAAGACAGAAACTCTGACTGGTCAAGAAAATAGGAA
TTCAGACCCAAATATCAGACTAGCTAAATTGGCCCAAGATGGGTCCATCATCTTAATCCGACCTCTGACT
TCAACACAGTGGCTCTGGCAAAACAGTGGCCATGGTACATGCCATGCCCTAGTGAGTAACAGAAAAG
TGGCATCAAAGGAATTGATCAAGGGAGGGAAAGTGAAGGTGCTCTGGTAGCAAAAGGAATGGAAAG
CTTAGACCCAGTGGCAAGGGAGGTGCTCTGGTAGCAAAAGGAATGGGTGCTCTGGTAGCAAAAGGA
TCAACACAGTGGCTCTGGCAAAACAGTGGCCATGGTACATGCCATGCCCTAGTGAGTAACAGAAAAG
AATGGTGGCCAGTGGCAAGGGAGGTGCTCTGGTAGCAAAAGGAATGGGTGCTCTGGTAGCAAAAGGA
GTAGAAGGTCAAGGCAGGTGCTCTGGTAGCAAAAGGAATGGGTGCTCTGGTAGCAAAAGGA
GGGAGGAAAAAGCTCCCCATGTGGCAACCCCTGACATGCCATGCCCTAGTGAGTAACAGAAAAG
AGACAGATTAAATCCAAAGGAATAGCAATTAAATGCCATTAGCAAAAGGTGCTCTGGTAGCAAAAGGA
GGAGGGGGTCTCTAACACCCCTAAATCTTAGAAGAGACTCTAACCTCTAACAGTGGCAATCC
TTAATTGACTCCCCATCTAACAGTGGCAATCCATGGAGGAATGGTGTGATAACCTCGGTGATA
ATACTAGAAGGTGGTCTCTAACAGTGGCAATCCATGGAGGAATGGTGTGATAACCTCGGTGATA
ACATAGAATGGTGGAGGGTACAGTGGCTAGAGAAAAATTAGTCCAAAGGAAATCCAAACT
GCCATCTAAC (SEQ ID NO:52)

FIG. 3B (SHEET 6 OF 26)

hMOR-1B2 (397 aa)

MDSSAAPTNASNCTDALAYSSCCSPAPSPGSWVNLSHLDGNLSDPCGPNRRTDLGGRDSLCPPTGSPSMITA
GLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLC
YIAVCHHPVKALDFRTPRNAKJINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTTWYWENNLKJC
CYGLMLRLKSVRMLSGSKEKDRLNLRITRMVLVVVAVFIVCWTPHIYVIKALVTPETTFQTVSWHFCIALGYTN
LYAFLDENFKRCFREFCPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQERRRQKS
(SEQ ID NO:53)

FIG. 3B (SHEET 7 OF 26)

hMOR-1B3 (2483 bp)

GTCCAAACTATAGAACATAGAATGTGAGGGCAGCACATAAGAAATAAGTCATGGGATTATTCATG
GACCAGCAATATGATGATAAAAGCCATCTAAC (SEQ ID NO:54)

hMOR-1B3 (403 aa)

MDSSAAPTNAASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSDLCPPTGSPSMITA
GLFGNFLVMYVIVRYTKMKTAATNIYIFNLADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLC
MSVDR
YIAVCHPVKALDFRTPRNAKINVCNWILSSAIGLPVMMATTKYRQGSIDCTLTSHPTWYWENLLKICVIFAFIMPVLITV
CYGLMILRLKSVRMLSGSKEKDNRNLRIRTRMVLVVVAVFIVCWTPHIYVIKALVTIPETTFQTVSWHFCLALGYTN
SCLNPV
LYAFLDENFKRCFREFCPIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQGPPAKFVADQLAGSS (SEQ ID NO:55)

FIG. 3C (SHEET 9 OF 26)

hMOR-1B4 (1251 bp)

CGGTGCTCCTGGCTACCTCGCACAGGGTCCCCGCCGTCAGTACATGGACAGCGCTGCCACCGAACG
CCAGCAATTGCAC TGATGCCCTGGGTACTCAAGTTGCTCCCCAGCAGCCCCGGTTCCCTGGTCAACTTGTCCCCA
CTTAGATGGCAACCTGTGCCACC ATGCCGGTCCCAGACCCAGCCCCACCTGGGGAGAGACGGCTCTGGAC
CGGCAGTCCCATGATCACGGCCATCACGGATCATGGCCCTACTCCATCGTGTGGCTGGGGCTTCGGAAAC
TTCCTGGTCATGTATGTGATTGTGATTACTACAGATAACCAAGATGAAGACTGCCACCAACATCTACGTTCAACCTTGCTCTGGC
AGATGGCCTAGCCACCAAGTACCCCTGGCCCTTCAGAGTGTGAATTACCTAATGGAAACATGGGCCATTGGAAACCATCCT
TGCAAGATAAGTGTGATAACTATAACATGGTCAACCAGCATATTGCCACCGATTCACCCCTCTGCAACCATGAGTGTGATCGAT
ACATTGGCAGTCTGCCACCCCTGCAAGGGCCTTAGATTTCGGTACTCCCCGAAATGCCAAAATTATCAAATGTCTGCAACTG
GATCCTCTAGCCATTGGTCTCAGTGGTCAATGTTICATGGCTACAAACAAAATAACAGGCAAGGTTCCATAGATTGTACAC
TAACATTCTCATCCAAACCTGGTAAGATCTGTGTTTCATCTGCCCTTCATTATGCCAGTG
CTCATCATACGGTGTGCTATGGACTGATGATCTGGCCTCAAGAGGTGTCCGGCATGCTCTGGCTCCAAAGAAAAGG
ACAGGAATCTCGAAGGGATCACCAAGGATGGTGTGTTCACTCGTCTGCTGGCTCATCGTCTGGA
TTACGTCATCATTAAGGCTTGGTTACAATCCCAGAAACTACGTTCCAGACTGTTCTGGCACTCTGCATTGCTCTAG
GTTACACAAACAGCTGCCCTCAACCCAGTCTGGATGAAAAGTCAAACGATGCTTCAGAGAGTCTG
TATCCCCAACCTCTCAACAAACTCCACACTCGAATTTCGTCAGAACACTAGAGACCACCCCCCTCCACGGCC
AATACAGTGGATAGAACTAATCATCAGAGCTGACTATGACATGGAAACCTTAAATTCTGTCCCC (SEQ ID NO:56)

hMOR-1B4 (389 aa)

MDSAAAPTNASNCTDALLYSSCCSPPSPGSWVNLSHLDGNLNSDP CGPNRTDLGGRDSDLCPPTGSPSMSMITAIMALYSIVCVV
GLFGNFLVMYVIVRYTKMKTATNIVENIALADALATSTLPFQS VNYLMGTWPFGTILCKIVISIDYNNMFTSIFTLC TMSVD
RYIAVCHPVKA LDERTPR NAKIINV CNWILSSAIGLPVUMEMATTK YRQGSIDC TLTFSHPTWYWWENLLKICVFIFAFIMPVLIT
VCYGLMLRLKSVRMLSGSKEKDRLNRIRTRMVLVVVAFFIVCWTPHIYVIKALVTIPETTFQTVSWHFCIALGYTNSCLNP
VLYAFLDENFKRCFREFCIPTSSNIEQQNSTRIRQNTRDHPS STANTVDR TNHQ S (SEQ ID NO:57)

hMOR-1B5 (1402 bp)

CGGTGCTCCTGGCTACCTCGCACAGCGGTGCCCGCCGTCACTGGACAGCAGCGCTGCCACCGAACG
CCAGCAATTGCACTGATGCCTTGGCGTACTCAAAGTTGCTCCAGCAGCCCCGGTCTGGGTCAACTTGTCCCCA
CTTAGATGGCAACCTGTCCGACCCATGGGGTCCGAAACCGCACCGACCTGGGGAGAGACAGCAGCCCTCCGAC
CGGCAGTCCCTCCATGATCACGGCCATCACGATCATGGCCCTACTCCATCGTGTGGTGGGGCTCTGGAAAC
TCCTGGTCATGTATGTGATTGTCAAGATAACACCAAGATGAAGACTGCCACCAACATCTACATTTCAACCTGCTCTGGC
AGATGCCCTAGGCCACCAAGTACCCCTGCCCTCCAGAGTGTGAATTACCTAATGGGAACATGGCCATTGGAAACCATCCT
TGCAAGATAAGTGTATCTCATAGATTACTATAACATGTTCAACCAGCATATTCAACCCCTGTGACCATGAGTGTGATCGAT
ACATTGGCAGTCTGCCACCCCTGTCAAGGCCCTAGATTTCGTTACTCCGTACTGGCTAACGGCTTAATGCAATTCAATGTC
GATGCCCTCTTCAGCCATTGGCTTCTGGTAAATGTTCATGGCTACAAACAAATACAGGCAAGGTTCCATAGATGTACAC
TAACATTCTCTCATCCAAACCTGGTACTGGAAAACCTGGTCAAGAGATCTGTGAAGATCTTGCCTCATTATGCCAGTG
CTCATCATTACCGTGTGCTATGGACTGATGATCTGGCTCAAGAGTGTCCGCATGCTCTGGCTCCAAGAAAAG
ACAGGAATCTCGAAGGGATACCAGGATGGGTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCT
TTACGTCTCATATTAAAGGCCCTGGTTACAATCCCAGAAAACCTACGTTCCAGACTGTTCTGGCACTCTGCTCTAG
GTTACACAAACAGCTGGCTCAACCCAGTCCTTATGCATTTCTGGATGAAAACCTCAAAACGATGCTTCAGAGAGTTCTG
TATCCCAACCTCTCCAAACATGAGCAACAAACTCCACTGGCAATTGAAACCTGGACTGTCACTGTGAAAATGCAAAGCCTGGCCACTG
AATAACAGTGGATAGAAACTAATCATCAGGTGGAAATTGAAACCTGGACTGTCACTGTGAAAGAGTCTAGAGGGTTAATTGAGTT
AGCTACAATGCAGGGTAGTCTCCATTCCCTCCAGGAAGAGTCTAGAGGGTTAATTGAGTTGGCAAGGGCTTGTA
ACTATTCAATGATTAGTTTAGAGCTGACTATGACATGAACCCCTAAATTCCCTGGTCCC (SEQ ID NO:58)

hMOR-1B5 (410 aa)

MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLDGNIISDPGPNRTDLGGGRDSLCPPTGSPSMITA
GLFGNFLVMYIVRYTKMKTAATNIYIFNLALADALATSLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLC
TMSVDR
YIAVCHPVKALDFRTPRNAKINVCNWLSSAIGLPVMFMATTKRYRQGSIDCTLFSHPTWYWE
CYGLMLRLKSVRMLSGSKEKDRNLRRITRMVLVVVAFIVCWTPHIYVIKALVTIPETTFQTVSWHFCLALGYTN
LYAFLDENFKRCFREFCPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQVELNLDCHCENAKPWPPLSYNAG (SEQ ID
NO:59)

hMOR-1Y (2601 bp)

CGGTGCTCTGGCTACCTCGCACAGCGGGTCCCCGGCGTCAGTACCGAACCCAGCCCCGGTTCTGGTCAACTTGTCCCCA
CCAGCAATTGCACCTGATGCCCTGGGTACTCAAGTTGCTCCCGACCATGGGGTCCGAACCCGACCTGGGGAGAGACAGCCTGCCCCCTCGAC
CTTAGATGGCAACCTGTCGCCACCATGGGGCATACGGCATACGGCTCATGGGGCTACTCCATCGTGTGGGGCTCTGGAAAC
CGGCAGTCCCATGATCACGGCCATCACGGATCATGGGCTACTCCATCGTGTGGGGAGAGACAGCCTGCTGGC
TTCCTGGTCATGTAATGTGATTGTGATTGTGAAAGACTGCCAACATCTACATTTCAACCTTGCTCTGGC
AGATGGCCTTAGCCACCAGTACCCCTGGCCCTCCAGAGTGTGAATTACCTAATGGGAACATGGCCATTGGAAACCATCCCT
TCCAAGAGATACTGATCTCCATAGATTACTATAACATGTTCACCGCATATCACCCCTCTGCCCCATGAGTGTGATCGAT
ACATTGCAGTCTGCCACCCCTGTCAGGCCTTAGATTCCGTACTCCCCGAAATGCCAAAATTATCAATGTCCTGCAACTG
GATCCTCTCTCAGGCCATGGTCTCCTGTAATGTTCATGGCTACAAACAAAATACAGGCAAGGTTCCATAGATTGTACAC
TAACATTCTCATCCAAACCTGGTACTGGGAAACCTGCTGAAGAGATCTGTTCATCTGCCCTTCATTATGCCAGTG
CTCATCATACCGTGTGCTATGGACTGATGATCTGGCCTCAAGAGTGTCCGCATGCTCTCTGGCTCCAAAGAAAAGG
ACAGGAATCTTCCAGGATCACCCAGGATGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGG
TTACGTCATCATTAAGGCTTGGTTACAATCCCAGAAACTACGTTCAGACTGTTCTGGCAGCTCTGCATTGCTCTAG
GTACACAAACAGCTGCCCTCAACCCAGTCCCTTAATGCATTCTGATGAAAACCTCAAAACGATGCTCAGAGACTCT
ATCCCCAACCTCTCCAAACATGGCAACAAACACTCCACACTCGAATTCTGTCAGAACACTAGAGACCAACCCCTCCACGGCC
AATACAGTGGATAAGACTAATCATCAGATCAGAGATCCAATATCAAACTTCCCAGGGTGTGTGATTCTGACAAC
CCACTGAGGCAATTCCATACAGCGCAAAGTGGAGTGGGATTGGCAGTTATCAAGGGACCTCCAGCCAAAGTTGTTG
CTGACCAACTTGGGGTCTGCTGAAAAGGGGGCTTACAGGTGTCCAAAGCCGTGTTACAGGCTTACAGGCT
ACACAGAAAAGACCTCATAAACACACAAATAACAGCTTAAAGGCTTAAAGGAGGCTTACCCATTGGCAATT
TTACAGAGGAGATAAACACTGATTTCATTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTT
CACAGAGGAGAAAGAACAGAACAGAACAGAACAGAACAGAACAGAACAGAACAGAACAGAACAGAACAGAAC
CTTCCCTGAGCGGCCCTAGTGAATCCGGCTTGCGCACCATCGGCCAAGCTGCATCATAAAGGAATT
TTTTTCATTCTGCCAGAGCAAAACACATGTGATAAAACATAGGCATTAGGCACCAAAATATCAGAC
TAGCTTAATTTGGGGTCCCATCTTAAATCCGACCTCTGACTGGTAAGAAATTGTTACCCATTGGCAGCATGCCAGGCT
CTTCCCTGAGCGGCCCTAGTGAATCCGGCTTGCGCACCATCGGCCAAGCTGCATCATAAAGGAATT
TTTTTCATTCTGCCAGAGCAAAACACATGTGATAAAACATAGGCATTAGGCACCAAAATATCAGAC
TAGCTTAATTTGGGGTCCCATCTTAAATCCGACCTCTGACTGGTAAGAAATTGTTACCCATTGGCAGCATGCCAGGCT
CAAACAGTGGTGAATGATCAAGGAGGCCAGAGAACAGACTCACCTATTGAGCAACACTGAGTTCAAGGCT
GGGGAAAGGTGAAATGATCAAGGAGGCCAGAGAACAGAACAGAACAGAACAGAACAGAACAGAACAGAAC
TTCTCGGTAGCAAAAGGATCTTCCGGCAATCCCTATTAGCTCAAGTTCGGCCTTAACCCCGCTTAACCC
GTCGGGATCCCTGATGCCAACCCATCACAGCAAGGAGGAAAGGAGAGAGAGAGAGAGAGAGAGAGAGAG
AATAGCAATTAAATATCCCATTAGCATCAAAGCTGTTCTTAGCCAAGAGGGACTTAAACACCCCTA
AATCTTAGAAGAGACCCCTAACCACTGGGGCTTAACCCCGCTTAACCC
GTCGGGATCCCTGATGCCAACCCATCACAGCAAGGAGGAAAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAG
AATAGCAATTAAATATCCCATTAGCATCAAAGCTGTTCTTAGCCAAGAGGGACTTAAACACCCCTA
AATCTTAGAAGAGACCCCTAACCACTGGGGCTTAACCCCGCTTAACCC
GTCGGGATCCCTGATGCCAACCCATCACAGCAAGGAGGAAAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAG
AATAGCAATTAAATATCCCATTAGCATCAAAGCTGTTCTTAGCCAAGAGGGACTTAAACACCCCTA
AATCTTAGAAGAGACCCCTAACCACTGGGGCTTAACCCCGCTTAACCC

AGTTGCAATCCCATGGAGGAATGCTGATAACCTCGGTGATAAGATAAAAAACCAAGCATAACTAGAAGTGTCTCTAA
ATTAAAATAACAGTAGTTGCTAGAGAAAAATTAGTCCAAACTATAGAACATAGAACATGGAGGATTTATTCAACAGCAATATGATAAAAGCCATCTAACCAAGGGC (SEQ
ID NO:60)

hMOR-1 Y (402 aa)

MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGGRDSLCPPTGSPSMITAITIMALYSIVCVV
GLFGNTFLVMMYVIVRYTKMKTATNYIFNLALADALATSTLPFQSVDNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDR
YIAVCHPVVKALDFRTPRNAKINVCNWILSSAIGLPVMEMATTKVRQGSIDCTLTSHPPTWVYWENLLKJICVFFIAFIMPVLITV
CYGLMLRLKSVRMLSGSKEKDNRNLRIRTRMVLVVVVAVFIVCWTPHIYVIKALVTIPETTFQTVSWHFCLALGYTNNSCLNPV
LYAFLDENFKRCFREFCPIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQIRDPISNLPRVSVF (SEQ ID NO:61)

FIG. 3F (SHEET 13 OF 26)

1

60

hMOR-1 (1) MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCCGPNRTDLGGRDSLCP
hMOR-1A (1) MDSSAAPTNASNCTDALAYSSCPAPSPGSWVNLSHLDGNLSDPCCGPNRTDLGGRDSLCP
hMOR-1B1 (1) MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCCGPNRTDLGGRDSLCP
hMOR-1B2 (1) MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCCGPNRTDLGGRDSLCP
hMOR-1B3 (1) MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCCGPNRTDLGGRDSLCP
hMOR-1B4 (1) MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCCGPNRTDLGGRDSLCP
hMOR-1B5 (1) MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCCGPNRTDLGGRDSLCP
hMOR-1O (1) MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCCGPNRTDLGGRDSLCP
hMOR-1X (1) MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCCGPNRTDLGGRDSLCP
hMOR-1Y (1) MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCCGPNRTDLGGRDSLCP
Consensus (1) MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCCGPNRTDLGGRDSLCP

61

120

hMOR-1 (61) PTGSPSMITAITIMALYSIVCGFLFGNFLVMMVVRYTKMKTTATNIYIFNLALADALAT
hMOR-1A (61) PTGSPSMITAITIMALYSIVCGFLFGNFLVMMVVRYTKMKTTATNIYIFNLALADALAT
hMOR-1B1 (61) PTGSPSMITAITIMALYSIVCGFLFGNFLVMMVVRYTKMKTTATNIYIFNLALADALAT
hMOR-1B2 (61) PTGSPSMITAITIMALYSIVCGFLFGNFLVMMVVRYTKMKTTATNIYIFNLALADALAT
hMOR-1B3 (61) PTGSPSMITAITIMALYSIVCGFLFGNFLVMMVVRYTKMKTTATNIYIFNLALADALAT
hMOR-1B4 (61) PTGSPSMITAITIMALYSIVCGFLFGNFLVMMVVRYTKMKTTATNIYIFNLALADALAT
hMOR-1B5 (61) PTGSPSMITAITIMALYSIVCGFLFGNFLVMMVVRYTKMKTTATNIYIFNLALADALAT
hMOR-1O (61) PTGSPSMITAITIMALYSIVCGFLFGNFLVMMVVRYTKMKTTATNIYIFNLALADALAT
hMOR-1X (61) PTGSPSMITAITIMALYSIVCGFLFGNFLVMMVVRYTKMKTTATNIYIFNLALADALAT
hMOR-1Y (61) PTGSPSMITAITIMALYSIVCGFLFGNFLVMMVVRYTKMKTTATNIYIFNLALADALAT
Consensus (61) PTGSPSMITAITIMALYSIVCGFLFGNFLVMMVVRYTKMKTTATNIYIFNLALADALAT

181

hMOR-1 (121) STLPFQSVNVLMGTVWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
hMOR-1A (121) STLPFQSVNVLMGTVWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
hMOR-1B1 (121) STLPFQSVNVLMGTVWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
hMOR-1B2 (121) STLPFQSVNVLMGTVWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
hMOR-1B3 (121) STLPFQSVNVLMGTVWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
hMOR-1B4 (121) STLPFQSVNVLMGTVWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
hMOR-1B5 (121) STLPFQSVNVLMGTVWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
hMOR-1O (121) STLPFQSVNVLMGTVWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
hMOR-1X (121) STLPFQSVNVLMGTVWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
hMOR-1Y (121) STLPFQSVNVLMGTVWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
Consensus (121) STLPFQSVNVLMGTVWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF

181

hMOR-1 (181) RTPRNAKINVCNWILSSAIGLPVMFMATTKYRQGSIDCRTLTSHPTWYWENLLKICVF
hMOR-1A (181) RTPRNAKINVCNWILSSAIGLPVMFMATTKYRQGSIDCRTLTSHPTWYWENLLKICVF
hMOR-1B1 (181) RTPRNAKINVCNWILSSAIGLPVMFMATTKYRQGSIDCRTLTSHPTWYWENLLKICVF
hMOR-1B2 (181) RTPRNAKINVCNWILSSAIGLPVMFMATTKYRQGSIDCRTLTSHPTWYWENLLKICVF
hMOR-1B3 (181) RTPRNAKINVCNWILSSAIGLPVMFMATTKYRQGSIDCRTLTSHPTWYWENLLKICVF
hMOR-1B4 (181) RTPRNAKINVCNWILSSAIGLPVMFMATTKYRQGSIDCRTLTSHPTWYWENLLKICVF
hMOR-1B5 (181) RTPRNAKINVCNWILSSAIGLPVMFMATTKYRQGSIDCRTLTSHPTWYWENLLKICVF
hMOR-1O (181) RTPRNAKINVCNWILSSAIGLPVMFMATTKYRQGSIDCRTLTSHPTWYWENLLKICVF
hMOR-1X (181) RTPRNAKINVCNWILSSAIGLPVMFMATTKYRQGSIDCRTLTSHPTWYWENLLKICVF
hMOR-1Y (181) RTPRNAKINVCNWILSSAIGLPVMFMATTKYRQGSIDCRTLTSHPTWYWENLLKICVF
Consensus (181) RTPRNAKINVCNWILSSAIGLPVMFMATTKYRQGSIDCRTLTSHPTWYWENLLKICVF

FIG. 4 (SHEET 15 OF 26)

241

300

hMOR-1 (241) FAFIMPVLIIITVCYGLMILRLKSVRMLSGSKEKDRNLLRRITRMVLVVVAVFIVCWTPHI
hMOR-1A (241) FAFIMPVLIIITVCYGLMILRLKSVRMLSGSKEKDRNLLRRITRMVLVVVAVFIVCWTPHI
hMOR-1B1 (241) FAFIMPVLIIITVCYGLMILRLKSVRMLSGSKEKDRNLLRRITRMVLVVVAVFIVCWTPHI
hMOR-1B2 (241) FAFIMPVLIIITVCYGLMILRLKSVRMLSGSKEKDRNLLRRITRMVLVVVAVFIVCWTPHI
hMOR-1B3 (241) FAFIMPVLIIITVCYGLMILRLKSVRMLSGSKEKDRNLLRRITRMVLVVVAVFIVCWTPHI
hMOR-1B4 (241) FAFIMPVLIIITVCYGLMILRLKSVRMLSGSKEKDRNLLRRITRMVLVVVAVFIVCWTPHI
hMOR-1B5 (241) FAFIMPVLIIITVCYGLMILRLKSVRMLSGSKEKDRNLLRRITRMVLVVVAVFIVCWTPHI
hMOR-1O (241) FAFIMPVLIIITVCYGLMILRLKSVRMLSGSKEKDRNLLRRITRMVLVVVAVFIVCWTPHI
hMOR-1X (241) FAFIMPVLIIITVCYGLMILRLKSVRMLSGSKEKDRNLLRRITRMVLVVVAVFIVCWTPHI
hMOR-1Y (241) FAFIMPVLIIITVCYGLMILRLKSVRMLSGSKEKDRNLLRRITRMVLVVVAVFIVCWTPHI
Consensus (241) FAFIMPVLIIITVCYGLMILRLKSVRMLSGSKEKDRNLLRRITRMVLVVVAVFIVCWTPHI

301

360

hMOR-1 (301) YVIIKALVTIPETTFQTVSWHFCIALGYTNCLNPVLYAFLDENFKRCFREFCIPPTSSNI
hMOR-1A (301) YVIIKALVTIPETTFQTVSWHFCIALGYTNCLNPVLYAFLDENFKRCFREFCIPPTSSNI
hMOR-1B1 (301) YVIIKALVTIPETTFQTVSWHFCIALGYTNCLNPVLYAFLDENFKRCFREFCIPPTSSNI
hMOR-1B2 (301) YVIIKALVTIPETTFQTVSWHFCIALGYTNCLNPVLYAFLDENFKRCFREFCIPPTSSNI
hMOR-1B3 (301) YVIIKALVTIPETTFQTVSWHFCIALGYTNCLNPVLYAFLDENFKRCFREFCIPPTSSNI
hMOR-1B4 (301) YVIIKALVTIPETTFQTVSWHFCIALGYTNCLNPVLYAFLDENFKRCFREFCIPPTSSNI
hMOR-1B5 (301) YVIIKALVTIPETTFQTVSWHFCIALGYTNCLNPVLYAFLDENFKRCFREFCIPPTSSNI
hMOR-1O (301) YVIIKALVTIPETTFQTVSWHFCIALGYTNCLNPVLYAFLDENFKRCFREFCIPPTSSNI
hMOR-1X (301) YVIIKALVTIPETTFQTVSWHFCIALGYTNCLNPVLYAFLDENFKRCFREFCIPPTSSNI
hMOR-1Y (301) YVIIKALVTIPETTFQTVSWHFCIALGYTNCLNPVLYAFLDENFKRCFREFCIPPTSSNI
Consensus (301) YVIIKALVTIPETTFQTVSWHFCIALGYTNCLNPVLYAFLDENFKRCFREFCIPPTSSNI

FIG. 4 (SHEET 16 OF 26)

361

420

hMOR-1 (361) EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP-----
 hMOR-1A (361) EQQNSTRIRQNTRDHPSTANTVDRTNHQVRSI-----
 hMOR-1B1 (361) EQQNSTRIRQNTRDHPSTANTVDRTNHQKIDLFQKSSLNCEHTKG-----
 hMOR-1B2 (361) EQQNSTRIRQNTRDHPSTANTVDRTNHQRERRQKSDW-----
 hMOR-1B3 (361) EQQNSTRIRQNTRDHPSTANTVDRTNHQGPPAKFVADQLAGSS-----
 hMOR-1B4 (361) EQQNSTRIRQNTRDHPSTANTVDRTNHQVELNLDCHCENAKPWPPLSYNAG-----
 hMOR-1B5 (361) EQQNSTRIRQNTRDHPSTANTVDRTNHQVELNLDCHCENAKPWPPLSYNAG-----
 hMOR-1O (361) EQQNSTRIRQNTRDHPSTANTVDRTNHQPPLAVSMAQIFTRYPPPTHREKTCNDYMKR-----
 hMOR-1X (361) EQQNSTRIRQNTRDHPSTANTVDRTNHQCLIPSLSCWALEHGCLVVYPGPLQGPLVRYD-----
 hMOR-1Y (361) EQQNSTRIRQNTRDHPSTANTVDRTNHQIRDPISNLPRVSVF-----
 Consensus (361) EQQNSTRIRQNTRDHPSTANTVDRTNHQ

421

446

hMOR-1 (401) ----- (SEQ ID NO:62)
 hMOR-1A (393) ----- (SEQ ID NO:63)
 hMOR-1B1 (407) ----- (SEQ ID NO:51)
 hMOR-1B2 (398) ----- (SEQ ID NO:53)
 hMOR-1B3 (404) ----- (SEQ ID NO:55)
 hMOR-1B4 (390) ----- (SEQ ID NO:57)
 hMOR-1B5 (411) ----- (SEQ ID NO:59)
 hMOR-1O (419) ----- (SEQ ID NO:64)
 hMOR-1X (421) LPAILHSSCLRGNTAPSPLGGAFLLS (SEQ ID NO:65)
 hMOR-1Y (403) ----- (SEQ ID NO:61)
 Consensus (388) (SEQ ID NO:66)

FIG. 4 (SHEET 17 OF 26)

rMOR-1A


Exon 3a ↓ Exon 3b
----AACCACCCAGGTATGCTTCTAGAATTACGGATAACATATAAAAATACCATATCTGGTA
N H Q V C A F * (SEQ ID NO: 67)
CCAGCTTAAGATTAAATCTTTAAGAAGGTCACTTGAGGCCAAAGTCC (SEQ ID NO: 68)

rMOR-1C1

Exon 3a ↓ Exon 7
----AACCACGCCAGGTATGCTTCTAGAATTACGGATAACATATAAAAATACCATATCTGGTA
N H Q P A L A V S V A Q I F T G Y P S P
Exon 8 ↓
ACTCATGGTGAACAAACCCCTGCAAGAGTTACAGGGACAGACCTAGACCCCTGTGGAAAGAACGTGGT
T H G E K P C K S Y R D R P R P C G R T W
CTTTGAAATCGCGTGCAGAATCCAATGTGGAGGCACCTCCATITGTGGAGGCCGATTAATCTATAA
S* L K S R A E S N V E H F H C G A A L I Y N
Exon 9a ↓
CAAATGTGAATTTCATCTAAACACAGGGATGCTAGTGAGAAGTTGGAGGTGCAGGC (SEQ ID NO: 69)
N V N F I * (SEQ ID NO: 70)

FIG. 5 (SHEET 18 OF 26)

rMOR-1C2



rMOR-1D




FIG. 5 (SHEET 19 OF 26)

rMOR-1B2

Exon 3a ↓ **Exon 5b**
 ----AACCCAGGAGCCTCAGTCAGTAGAGACATGATGTGAACCAACTGATTAAACAAG
 N H Q E P Q S V E T * (SEQ ID NO: 75)
 GTTTTCTGAACACTGAAATAAACACAATGTTAGAGGTTACTAGAGAAAATTCAATTACGGAAACCAAATGAGT
 GTGAGTGTATAACATTAAAGGCCTCAAGAGAGATTATTCAACTAACATGACCCAAAGCACCTAAACTGTGGTGATTAGATA
 CAAAGACAAATTCTAGAGCCTGGGACTAAAGAAATGTTAGCCCTCACACAGACAGGCCTCACACTCACTTAATGGAATGAGCAATTAGA
 TTAGTGAGAAAGATGGAGGAAGACTCGAAATTTCATATCTTGTGAACTCCACAGAAAACCAATAAGAATAACCAACCTGTC
 TGGACCCCTTGGTGGCTTACCC (SEQ ID NO: 76)

rMOR-1E

Exon 3a ↓ **Exon E**
 -----AACCACCAGGGAGCCAGAGT-TATGAGGATTAAATAACAAAAGACTTACCGCCCTTCAGGG
 N H O G A E L * (SEQ ID NO:77)
 AGCAGGCCAGGGAGGGCCCTTGGCCCCCAATGGTAGGTGCTCCCCACTTGCTGTCTCCCCATCA
 TTTCAAGCTATGGCTACCCGGCATAGCCTTATTCAAGTCTTCTGACTGACCTCAGATTATGCA
 GGAGACAGGAATGCTCATACCGAAGTGGAAAGTGGCTAAATGCAATTACACGTGAGCCAACACCC
 GCAGAGTCATCCCCACTCAAGGCATTAAACAAATTATCAAGGCAATTCTCTCTCTCTCTCTCT
 CTCTGTGCCCCCT
 CTTTTCTAAGCAGCCCCCT
 TTTCTCCAACCCAGGGATAAACATCTAGAGCAAGCAATTGAAACTATCTATAACAAACTGAGCT
 TGCTTTCATGGAGAAAAGGAAGGCATAGGAAGGCTGGCTCTTCCCTCCCTAGGGCTTCT
 TGTAGGGGTGTGGCTGCTTGGTAGCTCCCTAGGACACTGTTGGGGCTTCTATCCTGGCTGA
 AACCTTCTTAATCCAGCACATTCCCTGGTTT (SEQ ID NO:78)

rMOR-1B2 (1628 bp)

GTTCAGGGCTACCTAGTCGGCAGCAGGCCCCAGGGAAACACCAGCGACTGCT
CAAGCCCCCTTAGCTCAGGCCAAGTGTCCAGCTCCCCAGCACCTGGCTCAACTGTCCCACGGTTGATGGCAACCAAGTC
CGATCCATGGGTTCTGAACCCGCACCCGGCTGGGGAACGACAGCAGCCTGCCCCCATGGTGA
CACAGCCATTACCATCATGGCCCTACTCTATCGTGTGTAGGGCCTCTCGGAAACTCCCTGGTCAATGTATGTGA
TTGTAAGATAACACCAAAATGAAAGACTGCCAACACATCTACATTTCAACCCCTTGGAAACCATCCCTCTGCAAGAGTCGATTCA
TACACTGCCCTTCAGAGTGTCAACTACCTGATGGGAACATGGCCCTTGGAAACCATCCCTCTGCAACCATTCACCGCTACATTGCTGTCCACC
ATAGATTACTACACATGGCATATTCAACCCCTCTGCACCATGAGGCGTGGACCGCTACATTGCTGTCCACC
CAGTCAAAGCCCCCTGGATTTCGTACCCCCCGAAATGCCAAAATCGTCAACCGTCTGCAACTGGATCCCTCTGCCAT
CGGTCTGCCTGTAATGTTCATGGCAACCAAAATAACAGGCAGGGTCCATAGATTGCAACCTCACGTTCTCCACCCA
ACCTGGTACTGGGAGAACCTGCTCAAATCTGTGTCTTATCTTCGCTTCACTCATGCCGGTCTCATCATC
TACGGGCTTGATGATCTTACGACTCAAGAGCGTTCGCACTGCTATCGGGGCTCCAAAGAAAAGGACAGGAATTGGCAG
GATCACCCGGATGGTGTGGCTGGTGTGGCTGGTGTATTATCGTCTGCTGGACCCCCATCCACATCTACGTCA
GCGCTGATCACGATTCCAGAAACCACATTCAAGACCGTTCCCTGGCACTCTGCATTGCTTGGTTACACGAACAGCT
GCCTGAAATCCAGTTCTGGATGAAAACCTCAAGCGATGCTCAAGAAGGTTCTGCATCCCAACCC
GTCCACGATCGAACAGAAAACCTCCACTCGAGTCCGTCAGAACACTAGGGAAACATCCCTCCACGGCTAAATACAGTGG
TCCAACCAAGAGCCTCAGTAGAGACATGATGTGAACCAACTGATTAAACAAGGGTTCTGAAAC
ACTGAAATACAACAAATGTTAGAGGTACTAGAGAAAATTGTAGCCATTACGGAAACCAATGACCTAACATGAC
GTGAGTGTATACATTAAAGGCCCTCAGAGAGATTTCATGACTAACAAACATGACCTAACACTGTTGG
GATTAGATTACAAAGACAATTCTAGAGGCTGGGACTAAAGAAATGTTAGCTGCACACAGACAGGGCTCACACTCAG
TAATGGAATGAGCAAATTAGATTAGTGAAGAAGATGGGAAAGACTCGAAATATTTCATATCTTCCCTGTGGACTC
CACAGAAAACCAATAAGAATAAACCAACCTGTTGGACCCCTGGCTCTTAC (SEQ ID NO:79)

rMOR-1B2 (394 aa)

MDSSSTGPGNTSDCSDPLAQASCSPAPGSWLNLSHVVDGNQSDPCGLNRTGLGGNDLCPQTGSPSMVTAITIMALYSIVCVVG
LFGNFLVMYVIVRYTKMVKATATNYYFNLAADALATSTLPPFGLTILCKIVISIDYYNMFTSIFTLCITMSVDRY
IAVCHPVKAIDFRTPRNAKIVNVCNWLSSAIGLPVMEMATTKYRQGSIDCCTLTESHPTWYWWENLLKJCVCVIFAFIMPVLILTY
CYGLMLRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHYVIKALITPETTFQTVSWHFICIALGYTNNSCLNPVL
LRIPGMKTTSDASEEFCIPTTSSTIEQQNSTRVRQNTREHPSTANTVDRTNHQEPQSVE (SEQ ID NO:80)

FIG. 6A (SHEET 21 OF 26)

rMOR-1C1 (1433 bp)

rMOR-1C1 (451 aa)

MDSSTGPGNTSDCDPLAQASCSPAPGSWLNLSHV DGNQSDPCGLNRTGSPSMVT AITIM ALYSIVCVVG
LFGNFLVMMYVIVR YT KMKTA TN IYIFNLALADALATSTL PFGTILCKIVISIDYYNMFTSIFTLCTMSVDRY
IAVCHPVKA LDFRTPRNAKIVNVCNWILSSAIGLPVMFMATTKYRQGSIDC TLFSHPTWY WENLLKICVVFIAFIMPVLIIIV
CYGLMLRLKSVRM LSGSKEKD RNLRRTRMVLVVVA VFIVCWTHPIHYVVIKA LITPERTFQTVSWHFCIALGYTN SCLNPVLY
YAFLDENFKRCFREFCIPTSTS TIEQQNSTRVRQNTR EHPSTANTVDRTNHQPALAVSVAQIFTGYPSP THGEKPKCSYRDRPRP
CGRTWLSLK SRAESNV EHFHC GAA LIYNNVNF I (SEQ ID NO:82)

FIG. 6B (SHEET 22 OF 26)

rMOR-1C2 (1480 bp)

GTACAGGCCCTACCTAGTCGGCAGCAGGCACCATGGCACAGCAGCCGCCAGGGAAACACCAGCGACTGCT
CAGACCCCCCTAGGCTCAGGCAAGTGTGCTCCCCAGCACCTGGCTCAACTGTCCCACGGTGAATGGCAACCAAGTC
CGATCCATGGGGTCTGAACCCGCACCCGGCTGGGGAAACGACAGCAGCCCTGGCCATGGTGA
CACAGCCATTACCATCATGGCCCTACTCTATCGTGTCTATCGGAAACTCCCTGGTCATGTATGTGA
TTGTAAGATAACACAAAATGAAGAAGACTGCCCACCAACATCTACATTTCAACCTTGCTCTGGCAGACGCCCTAGCGACCAG
TACACTGCCCTTCAGAGTGTCAACTACCTGATGGAAACATGGCCCTTCGGAACCATCCCTCTGCAAGATCGTGAATCTCA
ATAGATTACTACAACATGTTCACAGCATATTCACCCCTCTGCACCATGAGCGTGGACCGCTACATGGCTGCTGCACC
CAGTCAAAGCCCTGGATTCCGTACCCCCGAAATGCCAAAATCGTCAACAGTCTGCAAACCTGGATCCCTCTGCCAT
CGTCTGCCATGGCAACCAACAAAATACAGGCCAGGGTCCATAGATTGCAACCCCTCACGTTCTCCACCCA
ACCTGGTACTGGAGAACCTGCTCAAAATCTGTCTTATCTTICGCTTTCATCATGCCGGTCTCCTCATCATCACTGTGTG
TTACGGCCCTGATGATGACTTACGACTCAAGAGCGTTCGCTATGCTATCGGGCTCAAGAGGAAACTGGACAGGAATCTGGCGCAG
GATCACCCGGATGGTGGCTGGTGTATTATCGTCTGCTGGACCCCCATCCACATCTACGTCACTCATCAAA
GCGCTGATCACGGATTCCAGAAACCATTTCAAGACCGTTCCCTGGCACTCTGCAATTGGTTACACCGAACAGCT
GCCTGAATCCAGTTACGGCCTTACGAGGATGCTCAGAGAGTTCAAGGGATGAAAAACTCAAGGGATGCTCAGAGGAAACTGGCA
ACGATCGAACAGCAAACACTCCACTCGACTCCGGTCAAGAACACTAGGGAAACATCCCTCCACGGCTAAATAACAGTGGATCGA
ACTAACCAACGGCCAGCCCTGGCAGTGTGGCCAGATCTTACAGGATATTCCTCCGACTCATGGTGAAAAAAC
CCTGCAAGAGTTACAGGGACAGACCTAGACCCCTGGAAAGAACGTTGGTCTTGAATCCAAATGTGG
AGCACTTCCATTGGAGGCCGATTAAACTATAACAATGAACAAACTAAATGGGCCAGTGTCCAGATGCCCTGC
GCACAGCTGGCTCGTGCAGGGCTCCGATTCTGAATTCCTGCTG (SEQ ID NO:83)

rMOR-1C2 (468 aa)

MDSSTGPGNTSDCDPLAQASCSPAPGSWLNLSHVDGNNQSDPCGLNRNTGLGGNDSLCPQTGSPSMVTAITIMALYSIVCVVG
LFGNFLVMMYVIVRYTKMKTAATNIYIFNLADALATSTLPPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRY
IAVCHPVKAALDFRTPRNAAKIVNVCNWLSSAIGLPVMFMATTKYRQGSIDCITLTFSHPTWYWEFLKICVFEFAFIMPVLITV
CYGLMLRLKSVRMLSGSKEKDRNLLRRRTRMVLVVVAVFIVCWTPHIYVVIKALITTPETTFQTVSWHFCIALGYTNNSCLNPVL
YAFLDENFKRCFREFCIPTSSTIEQNQNSTRVRQNTREHPSTANTVDRTNHQPALAVSVAQIFTGYPSPTHGEKPKCSYRDRPRP
CGRTWSLKSRAESNVEHFHCGAAALIYNNELKIGPVSWLQMPAHLVVRPW (SEQ ID NO:84)

FIG. 6C (SHEET 23 OF 26)

rMOR-1D (1385 bp)

GCTTACCTAGTCCGGCAGCAGGCCCTCAGCACCATGGACACCCTGGGAAACACCGGACTGCTCAGACC
CCTTAGCTCAGGCAAGTTGCTCCCCCAGCACCTGGCTCAAACCTGGCTCAGGCCCTGGGAAACGGCAGCCCTCAGACGG
ATGCGGGTCTGAACCGCAGGGCTTGGGGAAACGACGGCCTGTGCCCTAGACGGCAGGCCCTAGGGTAA
CATTACCATCATGGCCCTACTCTATCGTGTGTAGTGGCAGACGCCCTAGCGACCCAGTACACT
GATAACACAAATGAAAGACTGCCAACATCTACATTTCACCCCTTGCAAGATCGTGAATAGAT
GCCCTTCAAGAGTGTCAACTACCTGATGGGAACATGGGCCCTTCGGAAACCACATGGCCACCATGAGCGTGGACCGCTACATTGCTGCTGCCACCCAGTCA
TACTACAACATGTTCACCAAGCATATTCAACCCCTGCACCATGAGCGTGGACCGCTACATTGCTGCTGCCACCCAGTCA
AAGGCCCTGGATTTCGGTACCCCCCGAAATGCCAAAATGGCAACCGTCACTGGATCCTCTCTGCACCGTCTGCACGG
GCCTGTAATGTTCATGGCAACCAAAATACAGGCAGGGTCCATAGATTGCACCCCTCACGTTCTCCACCCAACCTGG
TACTGGAGAACCTGGCTCAAATCTGTGCTTTGCTCGCATGCTATGGCTCCATCATGCCGGCCTCATCATGCCGG
CCTGATGATCTTACGACTAAGAGCGTTCGGCATGCTATGGCTGGACCCCCATCCACATCTACGTCATCATCAAAGGGCTG
CCGGATGGTGGCTGGTGGCTGTGTTATCTGTTATCTGCTGGCTGGTGGCTGGTGGCTGGTGGCTGGTGGCTGGTGG
ATACCGATTCCAGAAACCACTTCAAGACCGTTCCCTGGACTTCTGCATTGCTTGGGTACACGAACAGCTGCTGA
ATCCAGTTACGCCTTACGAGGATGCTTCAGAGGTCTGCACTCGAGTCCGTAAGAACACTAGGGAAACATCCCTCAGGGCTAATACAGTGGATCGAAACTAAC
GAACAGCAAAACTCCACTCGAGTCCGTAAGAACACTAGGGAAACATCCCTCAGGGCTAATACAGTGGATCGAAACTAAC
CACCAGACCTAGACCCCTGTGGAAAGAACGGTGGCTTTGAAATCCAATGCGGTGCAAGAATCCATTGTGG
GCCGCATTAAATCTATAACAAATGAACTAAAAAATAGGGCCAGTGTCCAGATGCCCTGGCTCCAGATGCCCTGGCC
CCTGGTAATGAAACACGGGCTCCGATTCTGAATATCCTTCTGTG (SEQ ID NO:85)

rMOR-1D (387 aa)

MDSSSTGPGNTSDCSDPLAQASCSPAPGSQLNRLSHVDGNQSDPCGLNRRTGLGGNDLCPQTGPSMVTAITIMALYSIVCVVG
LFGNFLVMMYVIVRYTKMKTAATNTYIFNLALADALATSTLPFQSVNLYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRY
IAVCHPVKAALDFTRPRNAKIVNVCNWLSSAIGLPVMEMATTKYRQGSIDCTLTESHPTWYWENLLKICVVFVEAFIMPVLITV
CYGLMLRLKSVRMLSGSKKEKDRLNLRIRTRMVLVVVAVFIVCWTPIHYVIKALITPETTFQTVSWHFCIALGYTNNSCLNPVLYAFLDENFKRCFRREFCIPSTSIEQQNSTRVRQNTREHPSTANTVDRRTNHQT (SEQ ID NO:86)

rMOR-1E (2078 bp)

GTACAGCCTACCTAGTCCGAGGCCTCAGCACCATGGACAGCAGGCCAGGGAAACACCGCCAGGGACTGCT
CAGACCCCTAGCTCAGGCAAGTTGCTCCAGCACCCTGGCTCAACTTGTCCCACGCCCCCTGGATGGCAACCGTC
CGATCCATGCCGGTCTGAACCCGACGGGAACGACAGGCCCTGGCTCAGACCCGCAAGCCCTTCATGGT
CACAGCCATTACCATCATGGCCCTTAACCTCGTGTGTAGTGGGGCTCTGGAAACTCCTGGTCTGGTAGTGTGA
TGTAAGATAACACCAAAATGAAGACTGCCACCAACATCTACATTTCACCTGCTGGCAGACGCCCTAGCGACCAAG
TACACTGCCCTTCAGAGTGTCAACTACCTGATGGGAACATGGCCCTTCAGAACCTCCTGGCAGACGCCCTACATTGCT
ATAGATTACTACAACATGTTCAACCAGCATATTACCCCTCTGACCATGAGCGTGGACCGCTACATTGCT
CAGTCAAAGCCCTGGATTCCGTACCCCGAAATGCCAAACATGGCTCAACGTCATGGCAACTGGATCCT
CGGTCTGCCCTGTAATGGTCATGGCAACCAACCAAAATACAGGCAGGGGCTCATAGATTGCACCCCTCACGGTTCTCCACCC
ACCTGGTACTGGAGAACCTGCTCAAATCTGTCTTATCTCGCTTCATCATGCCGGTCCTCATCATC
TTACCGGCCTGATGATGCTTACGACTCAAGAGCGTTCGATGCTATCGGGCTCCAAAGAAAAGGACAGGAATCTGGCGCG
GATCACCCGGATGGTCTGGCTGGTCTGGCTGGATGGGGATGGGAAACACTCCAGACCGGTTCCGGC
GGCTGATCACGATTCCAGAAACCACATTACGGCTTACGCCCTCCCTGGATGAAACACTCCAGGG
GCCTGAATCCAGTTCTTACGCCCTCCCTGGATGAAACACTCCAGGG
ACGATCGAACAGCAAACCTCCACTGGCTGGCTGGGCTGGGCTGG
ACTAACCCAGGGAGCAGAGTTATGAGGATTAAATACAAAAAGACTACCACG
GGCCCTTGGCCCCACAATGGTAGGTGCTGTCCTCCACACATCT
GATGGCTACCCGGCATAGCCTTATTCAGTCCTGACTGACCT
GCTATGGGAAATGGGGTTCTGCTCATACGGTGGCTAATGCA
CTCAGGGAGCAGGAATGCTCATACGGTGGGAGTGG
CATGGGGTAATGGGGCAGAGTCATCCCCACTCA
AATCAGAGCCAGACAGAAATGGGGTTCTGCTCATACGGTGG
CATTGTTATCCACATCAACACATAACCCCTTACTTTCT
ACTTTGAAAGGGTAAGGGATTAAATTGATT
TGAAACTATCTATAACAAACTGAGGCTCAATCTTGGCATT
GGAAAGCTGGGCTCTCCCTCCAGGTGCTTCCCT
GTAGCTTCAGGACACTGGGGCTTATCC
CCAGCACATTCCTGTT
(SEQ ID NO:87)

FIG. 6E (SHEET 25 OF 26)

rMOR-1E (390 aa)

MDSSTGPANTSDCSDPLAQASCSPAPGSWLNLSHVDGNNQSDPCGLNRTGLGGNDSLCPQTGSPSMVTAITIMALYSIVCVVG
LFGNFLVMYVIVRYTKMKTTATNIYFNALADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSFTLCTMSVDRY
IAVCHIPVKALDFRTPRNAAKJVNVCNWLSSAIGLPVMMFMATTKYRQGSIDCTLTFSHPTWYWENILKICVFIFAFIMPVLIIIV
CYGLMILRLKSVRMLSGSKEKDRLNLRGITRMVLLVVAVFIVCWTPTHIIYVIKKALITIPETTFQTVSWHFCIALGYTNNSCLNPVL
YAFLDENFKRCFREFCPIPTSSTIEQQNSTRVRQNTREHPSTANTVDRTNHQGAEL (SEQ ID NO:88)

FIG. 6E (SHEET 26 OF 26)